Benzene, pyridine, and pyridazine derivatives

ABSTRACT

Disclosed are compounds and pharmaceutically acceptable salts of Formula I 
                         
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4  are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of Provisional Application No. 60/656,230, filed Feb. 25, 2005, Provisional Application No. 60/705,715, filed Aug. 4, 2005, and Provisional Application No. 60/727,965, filed Oct. 18, 2005.

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to benzene, pyridine, and pyridazine derivatives and more specifically to such compounds that are useful in the treatment and/or prevention of diseases and/or conditions related to cell proliferation, such as cancer, inflammation and inflammation-associated disorders, and conditions associated with angiogenesis. Compounds of the invention are also useful in the treatment and/or prevention of infectious diseases, in particular, fungal infections.

Description of the Related Art

Cancer is characterized by abnormal cellular proliferation. Cancer cells exhibit a number of properties that make them dangerous to the host, typically including an ability to invade other tissues and to induce capillary ingrowth, which assures that the proliferating cancer cells have an adequate supply of blood. A hallmark of cancerous cells is their abnormal response to control mechanisms that regulate cell division in normal cells and continue to divide until they ultimately kill the host.

Angiogenesis is a highly regulated process under normal conditions, however many diseases are driven by persistent unregulated angiogenesis. Unregulated angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. For example, ocular neovascularization has not only been implicated as the most common cause of blindness, but also is believed the dominant cause of many eye diseases. Further, in certain existing conditions, for example arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage, or in the case of diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also dependent on angiogenesis (Folkman, J., Cancer Research, 46, 467-473 (1986), Folkman, J., Journal of the National Cancer Institute, 82, 4-6 (1989). It has been shown, for example, that tumors which enlarge to greater than 2 mm must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the circulation and metastasize to distant sites such as liver, lung or bone (Weidner, N., et al., The New England Journal of Medicine, 324(1), 1-8 (1991). Under conditions of unregulated angiogenesis, therapeutic methods designed to control, repress, and/or inhibit angiogenesis could lead to the abrogation or mitigation of these conditions and diseases.

Inflammation is related to a variety of disorders such as pain, headaches, fever, arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis, psoriasis, eczema, burns, dermatitis, inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome, ulcerative colitis, vascular diseases, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, hypersensitivity, conjunctivitis, gingivitis, post-injury swelling, myocardial ischemia, and the like.

Heat-shock protein 90 (HSP-90) is a cellular chaperone protein required for the activation of several eukaryotic protein kinases, including the cyclin-dependent kinase CDK4. Geldanamycin, an inhibitor of the protein-refolding activity of HSP-90, has been shown to have antiproliferative and antitumor activities.

HSP-90 is a molecular chaperone that guides the normal folding, intracellular disposition and proteolytic turnover of many key regulators of cell growth and survival. Its function is subverted during oncogenesis to make malignant transformation possible and to facilitate rapid somatic evolution, and to allow mutant proteins to retain or even gain function. Inhibition of HSP-90 will slow those process thus has potential therapeutic use (Whitesell L, Lindquist, S L, Nature Rev. Cancer, 2005, 10, 761-72).

Ansamycin antibiotics, e.g., herbimycin A (HA), geldanamycin (GM), and 17-allylaminogeldanamycin (17-AAG) are thought to exert their anticancerous effects by tight binding of the N-terminus pocket of HSP-90, thereby destabilizing substrates that normally interact with HSP-90 (Stebbins, C. et al. Cell 1997, 89, 239-250). This pocket is highly conserved and has weak homology to the ATP-binding site of DNA gyrase (Stebbins, C. et al., supra; Grenert, J. P. et al. J. Biol. Chem. 1997, 272, 23843-50).

In vitro and in vivo studies have demonstrated that occupancy of this N-terminal pocket by ansamycins and other HSP-90 inhibitors alters HSP-90 function and inhibits protein folding. At high concentrations, ansamycins and other HSP-90 inhibitors have been shown to prevent binding of protein substrates to HSP-90 (Scheibel, T. H. et al. Proc. Natl. Acad. Sci. USA 1999, 96, 1297-302; Schulte, T. W. et al. J. Biol. Chem. 1995, 270, 24585-8; Whitesell, L., et al. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328). Ansamycins have also been demonstrated to inhibit the ATP-dependent release of chaperone-associated protein substrates (Schneider, C. L. et al. Proc. Natl. Acad. Sci., USA 1996, 93, 14536-41; Sepp-Lorenzino et al. J. Biol. Chem. 1995, 270, 16580-16587). In either event, the substrates are degraded by a ubiquitin-dependent process in the proteasome (Schneider, C. L., supra; Sepp-Lorenzino, L., et al. J. Biol. Claim. 1995, 270, 16580-16587; Whitesell, L. et al. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328). HSP-90 substrate destabilization occurs in tumor and non-transformed cells alike and has been shown to be especially effective on a subset of signaling regulators, e.g., Raf (Schulte, T. W. et al., Biochem. Biophys. Res. Commun. 1997, 239, 655-9 Schulte, T. W., et al., J. Biol. Chem. 1995, 270, 24585-8), nuclear steroid receptors (Segnitz, B.; U. Gehring J. Biol. Chem. 1997, 272, 18694-18701; Smith, D. F. et al. Mol. Cell. Biol. 1995, 15, 6804-12), v-Src (Whitesell, L., et al. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328) and certain transmembrane tyrosine kinases (Sepp-Lorenzino, L. et al. J. Biol. Chez. 1995, 270, 16580-16587) such as EGF receptor (EGFR) and HER2/Neu (Hartmann, F., et al. Int. J. Cancer 1997, 70, 221-9; Miller, P. et al. Cancer Res. 1994, 54, 2724-2730; Mimnaugh, E. G., et al. J. Biol. Clzem. 1996, 271, 22796-801; Schnur, R. et al. J. Med. Chenu. 1995, 38, 3806-3812), CDK4, and mutant p53. Erlichman et al. Proc. AACR 2001, 42, abstract 4474. The ansamycin-induced loss of these proteins leads to the selective disruption of certain regulatory pathways and results in growth arrest at specific phases of the cell cycle (Muise-Heimericks, R. C. et al. J. Biol. Chez. 1998, 273, 29864-72), and apoptosis, and/or differentiation of cells so treated (Vasilevskaya, A. et al. Cancer Res., 1999, 59, 3935-40). Inhibitors of HSP-90 thus hold great promise for the treatment and/or prevention of many types of cancers and proliferative disorders, and also hold promise as traditional antibiotics.

Inhibition of HSP-90 is also known to result in up regulation of the expression of the chaperone HSP70. HSP70 up regulation is considered to be of therapeutic benefit for treatment of a wide range of neurodegenerative diseases including, but not limited to: Alzheimer's disease; Parkinson's disease; Dementia with Lewy bodies; Amyotropic lateral scleriosis (ALS); Polyglutamine disease; Huntington's disease; Spinal and bulbar muscular atrophy (SBMA); and Spinocerebellar ataxias (SCA1-3,7). Therefore, the compounds described in the invention are of potential therapeutic use for treatment of such neurodegenerative diseases (Muchowski, P. J., Wacker J. L., Nat. Rev. Neurosci. 2005, 6, 11-22; Shen H. Y., et al. J. Biol. Chem. 2005, 280, 39962-9).

Inhibition of HSP-90 also has anti-fungal activity, both as a stand alone therapy and in combination with standard anti-fungal therapies such as the azole class of drugs. Therefore, the compounds described in the invention are of potential therapeutic use for treatment of fungal infections including, but not limited to, life threatening systemic fungal infections (Cowen, L. E., Lindquist, S., Science 2005, 309, 2185-9).

Inhibition of HSP-90 also has antimalarial activity; thus, inhibitors of this protein are useful as antimalarial drugs.

Therefore, there is a continuing need in the art for new methods of treating cancer, inflammation and inflammation-associated disorders, and conditions or diseases related to uncontrolled angiogenesis.

SUMMARY OF THE INVENTION

In a broad aspect, the invention encompasses the compounds of formula I shown below, pharmaceutical compositions containing those compounds and methods employing such compounds or compositions in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like.

The invention provides compounds of formula I,

or a pharmaceutically acceptable salt thereof, wherein R₃ and R₄ are independently

-   -   (a) H,     -   (b) halo, or     -   (c) a C₁-C₁₅ alkyl group where up to six of the carbon atoms in         said alkyl group are optionally replaced independently by R₂₂,         carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S,         SO₂, or SO, with the proviso that two O atoms, two S atoms, or         an O and S atom are not immediately adjacent each other, wherein         -   R₂₂ is             -   (i) heteroaryl,             -   (ii) aryl,             -   (iii) saturated or unsaturated C₃-C₁₀ cycloalkyl, or             -   (iv) saturated or unsaturated C₂-C₁₀ heterocycloalkyl,                 wherein             -   each aryl, heteroaryl, saturated or unsaturated                 cycloalkyl, or saturated or unsaturated                 heterocycloalkyl, independently, is optionally                 substituted with at least one group, which independently                 is hydroxy, halo, amino, cyano, carboxy, carboxamido,                 nitro, oxo, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl,                 —SO₂-aryl, —SO—(C₁-C₆)alkyl, —SO-aryl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, (C₁-C₆)alkoxy, or                 mono- or di-(C₁-C₁₀)alkylamino; and         -   each R₂₂ is optionally fused to a C₆-C₁₀ aryl group, C₅-C₈             saturated cyclic group, or a C₅-C₁₀ heterocycloalkyl group;     -   wherein each (c) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃,         wherein         -   Z is OR₀ or —N(R₃₀)₂, wherein             -   each R₃₀ is independently —H or C₁-C₆ alkyl, or N(R₃₀)₂                 represents pyrrolidinyl, piperidinyl, piperazinyl,                 azepanyl, 1,3- or 1,4-diazepanyl, or morpholinyl, each                 of which is optionally substituted with hydroxy, amino,                 aminoalkyl, C₁-C₆ alkyl, mono- or di(C₁-C₆)alkylamino,                 C₁-C₆ alkoxy, or halogen;             -   R_(O) is —H, —C₁-C₁₀ alkyl, —C₂-C₁₀ alkenyl, —C₂-C₁₀                 alkynyl, aryl, heteroaryl, or —C₁-C₆ acyl;         -   R₂₃ is             -   (1) heteroaryl,             -   (2) aryl,             -   (3) saturated or unsaturated C₅-C₁₀ cycloalkyl, or             -   (4) saturated or unsaturated C₅-C₁₀ heterocycloalkyl,                 and         -   the R₂₃ groups are optionally substituted at least one group             which is independently hydroxy, oxo, halo, amino, cyano,             nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂-aryl,             —SO—(C₁-C₆)alkyl, —SO-aryl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl,             —SO₂NH-aryl, (C₁-C₆)alkoxy, or mono- or             di-(C₁-C₁₀)alkylamino;     -   or R₃ and R₄ together with the atoms to which they are attached         form a 5-12 membered mono-, bi-, or tricyclic ring system fused         to the ring containing Q₁ and Q₂, where the 5-12 membered ring         is partially unsaturated or aromatic and optionally contains one         or two of oxygen, S(O)_(m) where m is 0, 1, or 2, nitrogen, or         NR₃₃ where R₃₃ is hydrogen or C₁-C₆ alkyl;     -   R₇ is O, S, NH, N—OH, N—NH₂, N—NHR₂₂, N—NH—(C₁-C₆ alkyl),         N—O—(C₀-C₆)alkyl-R₂₂, or N—(C₁-C₆ alkoxy optionally substituted         with carboxy);     -   Y is N or CR_(C), wherein         -   each R_(C) independently is hydrogen, halogen, cyano, nitro,             —C(O)R_(C′), C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl,             C₁-C₁₀ haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇             cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl, aryl, or             heteroaryl, wherein             -   each alkyl, aryl, cycloalkyl, heterocycloalkyl, and                 heteroaryl group is optionally substituted with from 1-4                 groups that are independently C₁-C₆ alkyl, C₁-C₆ alkoxy,                 halogen, hydroxy, amino, mono- or di-(C₁-C₆)alkylamino,                 cyano, nitro, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy,                 carboxamide, heterocycloalkyl, aryl, or heteroaryl,                 wherein                 -   the aryl and heteroaryl groups are optionally                     substituted with from 1-4 groups that are                     independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen,                     hydroxy, amino, mono- or di-(C₁-C₆)alkylamino,                     halo(C₁-C₆)alkyl, or carboxamide;             -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂,                 wherein                 -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                     cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, C₁-C₁₀ alkyl, C₁-C₁₀                 haloalkyl, C₃-C₇ cycloalkyl, heterocycloalkyl, C₁-C₆                 acyl, aryl, or heteroaryl, wherein                 -   each alkyl, cycloalkyl, heterocycloalkyl, aryl, and                     heteroaryl group is optionally substituted with from                     1-4 groups that are independently C₁-C₆ alkyl, C₁-C₆                     alkoxy, halogen, hydroxy, amino, mono- or                     di-(C₁-C₆)alkylamino, nitro, halo(C₁-C₆)alkyl,                     halo(C₁-C₆)alkoxy, or carboxamide;     -   X₁ is N or CR_(C);     -   Q₁, Q₂, and Q₃ are independently N or CR_(Q), wherein one and         only one of Q₁, Q₂, and Q₃ is C—R₂₁, and wherein         -   each R_(Q) is independently hydrogen, halogen, —N(R_(N))₂,             C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₇ cycloalkyl, aryl, or             heteroaryl, or R₂₁, wherein         -   each alkyl, cycloalkyl, aryl, and heteroaryl group is             optionally substituted with from 1-4 groups that are             independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy,             amino, mono- or di-(C₁-C₆)alkylamino, halo(C₁-C₆)alkyl,             halo(C₁-C₆)alkoxy, or carboxamide;         -   R₂₁ is cyano, —C(O)OH, —C(O)—O(C₁-C₆alkyl), or a group of             the formula

wherein

-   -   -   -   R₁ and R₂ are independently H, hydroxy, C₁-C₆ alkyl,                 C₂-C₆ alkenyl, C₂-C₆ alkynyl, heteroaryl, aryl, C₃-C₈                 cycloalkyl, heterocycloalkyl, wherein                 -   each alkyl, cycloalkyl, heterocycloalkyl, aryl, and                     heteroaryl group is optionally substituted with from                     1-4 groups that are independently C₁-C₆ alkyl, C₁-C₆                     alkoxy, halogen, hydroxy, amino, mono- or                     di-(C₁-C₆)alkylamino, nitro, halo(C₁-C₆)alkyl,                     halo(C₁-C₆)alkoxy, or carboxamide;

        -   or R₁ and R₂ together with the nitrogen to which they are             both attached, form a heterocycloalkyl which optionally             contains one or more additional heteroatoms which are,             independently, O, N, S, or N(R_(CN));

        -   and

        -   X₄ is O, S, NH, NOH, N—NH₂, N—NHaryl, N—NH—(C₁-C₆ alkyl), or             N—(C₁-C₆ alkoxy);             X₂ and X₃ are independently C, O, N, or S(O)_(p) wherein

    -   p is 0, 1, or 2; and         n is 0, 1, 2, 3, or 4;         provided that when

    -   (i) X₂ is C, then         -   R₅ and R₆ are independently H, C₁-C₆ alkyl, or aryl, wherein             the aryl is optionally substituted with from 1-4 groups that             are independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen,             hydroxy, amino, mono- or di-(C₁-C₆)alkylamino, nitro,             halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, or carboxamide,         -   or wherein any two adjacent substituted aryl positions,             together with the carbon atoms to which they are attached,             form an unsaturated cycloalkyl or heterocycloalkyl; or         -   R₅ and R₆ together with the carbon to which they are             attached form a 3-8 membered ring;

    -   (ii) X₂ is N, then         -   R₆ is absent and R₅ is H or C₁-C₆ alkyl;

    -   (iii) X₃ is C, then         -   it is substituted with two groups that are independently H             or C₁-C₆ alkyl, or mono- or             di-(C₁-C₆)alkylamino(C₁-C₆)alkyl; and

    -   (iv) X₂ is O or S(O)_(p), then R₆ and R₅ are absent.

The invention also includes intermediates that are useful in making the compounds of the invention.

The invention also provides pharmaceutical compositions comprising a compound or pharmaceutically acceptable salt of Formula I and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent.

The invention further provides methods of treating disease such as cancer, inflammation, arthritis, angiogenesis, and infection in a patient in need of such treatment, comprising administering to the patient a compound or pharmaceutically acceptable salt of Formula I, or a pharmaceutical composition comprising a compound or salt of Formula I.

The invention also provides the use of a compound or salt according to Formula I for the manufacture of a medicament for use in treating cancer, inflammation, arthritis, angiogenesis, or infection.

The invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.

The invention also provides methods of treating a disease or condition related to cell proliferation comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need of such treatment.

The invention also provides methods of treating a disease or condition related to cell proliferation comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need of such treatment, where the disease of condition is cancer, inflammation, or arthritis.

The invention further provides methods of treating a subject suffering from a disease or disorder of proteins that are either client proteins for HSP-90 or indirectly affect its client proteins, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or salt of Formula I.

The invention further provides methods of treating a subject suffering from a disease or disorder of proteins that are either client proteins for HSP-90 or indirectly affect its client proteins, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or salt of Formula I, wherein the HSP-90 mediated disorder is selected from the group of inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases and malignant disease.

The invention further provides methods of treating a subject suffering from a fibrogenetic disorder of proteins that are either client proteins for HSP-90 or indirectly affect its client proteins, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound or salt of Formula I, wherein the fibrogenetic disorder is selected from the group of scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis.

The invention provides methods of protecting a subject from infection caused by an organism selected from Plasmodium species, preferably Plasmodium falciparum. These methods comprising administering a compound or salt of Formula I, preferably in an effective amount, to a subject at risk of infection due to exposure to such organism.

The invention additionally provides methods of reducing the level of infection in a subject where the infection is caused by an organism selected from Plasmodium species, again preferably Plasmodium falciparum. These methods comprise administering to an infected subject an effective amount of a compound or salt of Formula I.

The invention further provides methods for treating a patient infected with a metazoan parasite. These methods involve administering an amount of a compound of the invention effective to kill the parasite.

The invention further provides methods for treating a patient infected with a metazoan parasite wherein the parasite is Plasmodium falciparum. These methods involve administering an amount of a compound or salt of the invention effective to kill the parasite.

The invention further provides a compound or pharmaceutical composition thereof in a kit with instructions for using the compound or composition.

The invention further provides compounds that may be administered alone or in combination with other drugs or therapies known to be effective to treat the disease to enhance overall effectiveness of therapy.

The invention further provides methods for treating a fungal infection in a patient in need of such treatment, comprising administering an effective amount of a compound or salt of Formula I and an optional anti-fungal agent or drug.

DETAILED DESCRIPTION OF THE INVENTION

In Formula I, R₃ and R₄ are, as noted above, independently (a) hydrogen, (b) halo, or (c) an alkyl group having from 1-15 carbon atoms. All, but no more than about six, of the carbon atoms in the alkyl group may be replaced independently by the various groups listed above in connection with Formula I.

Thus, when the alkyl group is methyl, i.e., a one carbon atom alkyl group, replacement of that carbon atom with, for example, nitrogen or sulfur, the resulting group will not be an alkyl group but instead will be an amino or thio group, respectively. Similarly, when the carbon atom being replaced terminates the alkyl group, the terminal group will become another moiety such as pyrimidinyl, amino, phenyl, or hydroxy.

Replacement of a carbon atom with a group such as, for example, oxygen, nitrogen, or sulfur will require appropriate adjustment of the number of hydrogens or other atoms required to satisfy the replacing atom's valency. Thus, when the replacement is N or O, the number of groups attached to the atom being replaced will be reduced by one or two to satisfy the valency of the nitrogen or oxygen respectively. Similar considerations will be readily apparent to those skilled in the art with respect to replacement by ethenyl and ethynyl.

Thus, replacement as permitted herein results in the term “C₁-C₁₅ alkyl” as defined in connection with Formula I encompassing groups such as, but not limited to:

-   -   amino, hydroxy, phenyl, benzyl, propylaminoethoxy,         butoxyethylamino, pyrid-2-ylpropyl, diethylaminomethyl,         pentylsulfonyl, methylsulfonamidoethyl,         3-[4-(butylpyrimidin-2-yl)ethyl]phenyl, butoxy, dimethylamino,         4-(2-(benzylamino)ethyl)pyridyl, but-2-enylamino,         4-(1-(methylamino)pent-3-en-2-ylthio)phenyl,         2-(N-methyl-hexanamido)ethoxy)methyl, and         4-(((3-methoxy-4-(4-methyl-1H-imidazol-2-yl)but-1-enyl)(methyl)amino)-methyl)phenyl.

Preferred compounds of Formula I include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀-haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Even more preferred compounds of Formula I include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Additional preferred compounds of Formula I include those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Most preferred compounds of Formula I include those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, hydroxy, carboxy,         carboxamido, oxo, halo, amino, C₁-C₆ alkoxy, mono- or         di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Additional preferred compounds of Formula I include those where R₃ and R₄ are independently hydrogen, halo, or —OR_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Most preferred compounds of Formula I include those where R₃ and R₄ are independently hydrogen, halo, or —OR_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, hydroxy, carboxy,         carboxamido, oxo, halo, amino, C₁-C₆ alkoxy, mono- or         di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Preferred compounds of Formula I include those where X₁ is carbon optionally substituted with C₁-C₆ alkyl, more preferably C₁-C₃ alkyl. Other preferred compounds of Formula I are those where X₁ is carbon optionally substituted with C₁-C₆ alkyl and Y is CR_(C) wherein R_(C) is —H, C₁-C₆ alkyl, C₁-C₃ haloalkyl, C₃-C₇ cycloalkyl, or C₃-C₇ cycloalkyl(C₁-C₆)alkyl. More preferably, in compounds of Formula I, X₁ is carbon optionally substituted with C₁-C₂ alkyl and Y is CR_(C) wherein R_(C) is —H, C₁-C₄ alkyl, C₁-C₃ haloalkyl, cyclopropyl, or cyclopropyl(C₁-C₂)alkyl.

Still more preferred compounds of Formula I are those where X₁ is CH. Other more preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is —H, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₃-C₅ cycloalkyl, or C₃-C₅ cycloalkyl(C₁-C₂)alkyl. Even more preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is —H, methyl, ethyl, trifluoromethyl, cyclopropyl, or cyclopropylmethyl. Particularly preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is methyl, ethyl, or cyclopropyl. Other particularly preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is trifluoromethyl. Other particularly preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is methyl. Other particularly preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is ethyl. Other particularly preferred compounds of Formula I are those where X₁ is CH and Y is CR_(C) wherein R_(C) is cyclopropyl.

Still other preferred compounds of formula I are those where X₁ is CH, Y is CR_(C) wherein R_(C) is —H, C₁-C₃ alkyl, C₁-C₃ haloalkyl, or C₃-C₇ cycloalkyl, and R₃ is amino or C₁-C₃ alkylamino substituted on the amino or the alkyl with an optionally substituted aryl, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl group. Preferred substituents on these cyclic groups are hydroxy, C₁-C₃ alkoxy, oxo, halo, C₁-C₃ alkyl, amino, mono- or di-C₁-C₃alkylamino, and nitro. More preferably the optional substituents on these cyclic groups are hydroxy, C₁-C₃alkoxy, and oxo. These cyclic groups are optionally substituted with from 1-4, preferably 1-3 of these substituents.

Still more preferred compounds of Formula I are those where X₁ is N. Other more preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is —H, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₃-C₅ cycloalkyl, or C₃-C₅ cycloalkyl(C₁-C₂)alkyl. Even more preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is —H, methyl, ethyl, trifluoromethyl, cyclopropyl, or cyclopropylmethyl. Particularly preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is methyl, ethyl, or cyclopropyl. Other particularly preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is trifluoromethyl. Other particularly preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is methyl. Other particularly preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is ethyl. Other particularly preferred compounds of Formula I are those where X₁ is N and Y is CR_(C) wherein R_(C) is cyclopropyl.

Still other preferred compounds of formula I are those where X₁ is N, Y is CR_(C) wherein R_(C) is —H, C₁-C₃ alkyl, C₁-C₃ haloalkyl, or C₃-C₇ cycloalkyl and R₃ is amino or C₁-C₃ alkylamino substituted on the amino or the alkyl with an optionally substituted aryl, optionally substituted heterocycloalkyl, or optionally substituted cycloalkyl group. Preferred substituents on these cyclic groups are hydroxy, C₁-C₃alkoxy, oxo, halo, C₁-C₃alkyl, amino, mono- or di-C₁-C₃alkylamino, and nitro. More preferably the optional substituents on these cyclic groups are hydroxy, C₁-C₃alkoxy, and oxo. These cyclic groups are optionally substituted with from 1-4, preferably 1-3 of these substituents.

Other preferred compounds of Formula I are those where Q₃ is CR₂₁, wherein

R₂₁ is a group of the formula,

R₇ is O; and

Y is CR_(C), wherein R_(C) is hydrogen, C₁-C₃ alkyl, C₃-C₅ cycloalkyl, trifluoromethyl, or C₃-C₅ cycloalkyl(C₁-C₂)alkyl. Such compounds are compounds of Formula II herein.

Other preferred compounds of Formula II are those where, R₃ and R₄ are, as noted above, independently (a) hydrogen, (b) halo, or (c) an alkyl group having from 1-15 carbon atoms. All, but no more than about six, of the carbon atoms in the alkyl group may be replaced independently by the various groups listed above in connection with Formula I.

Other preferred compounds of Formula I are those where Q₃ is CR₂₁, wherein

R₂₁ is a group of the formula,

and X₃ is C substituted with R_(9a) and R_(9b), wherein R_(9a) and R_(9b) are independently H or C₁-C₆ alkyl. Such compounds are hereinafter compounds of Formula III.

Other preferred compounds of Formula I are those where Q₃ is CR₂₁, wherein

R₂₁ is a group of the formula,

and Q₁ and Q₂ are independently C substituted with R_(10a) and R_(10b) respectively, wherein R_(10a) and R_(10b) are independently H or C₁-C₆ alkyl. Such compounds are hereinafter compounds of Formula IV.

Other preferred compounds of Formula I are those where Q₃ is CR₂₁, wherein

-   -   R₂₁ is a group of the formula,

and

-   -   X₁ is C substituted with R₁₁ where R₁₁ hydrogen, halogen, cyano,         nitro, —C(O)R_(C′), C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀         alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇         cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl, aryl, or heteroaryl,         wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;                 each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl. Such compounds are                 hereinafter compounds of Formula V.

Preferred compounds of Formula V are those where R₁₁ is hydrogen, halogen, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, aryl, or heteroaryl.

More preferred compounds of Formula V are those where R₁₁ is H or C₁-C₆ alkyl.

Other preferred compounds of Formula I are those where Q₃ is CR₂₁, wherein

-   -   R₂₁ is a group of the formula,

and X₁ is N. Such compounds are hereinafter compounds of Formula Va.

Other preferred compounds of Formula I are those where Q₃ is CR₂₁, wherein

R₂₁ is a group of the formula,

and X₂ is C substituted with R₅ and R₆, wherein R₅ and R₆ are independently H or C₁-C₄ alkyl. Such compounds are hereinafter compounds of Formula VI.

Preferred compounds of any of Formulas I-VI include compounds where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

More preferred compounds of the invention are those of Formulas I-VI where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

More preferred compounds of the invention are those of Formulas I-VI where R₄ is H, C₁-C₄ alkyl or halogen. Preferred compounds of Formulas II-VI include those where X₁ is carbon optionally substituted with C₁-C₃ alkyl(preferably methyl) and Y is CR_(C) wherein R_(C) is C₁-C₂ alkyl, trifluoromethyl, cyclopropyl, or cyclopropyl(C₁-C₂)alkyl. More preferably in compounds of Formulas II-VI, X₁ is CH and Y is CR_(C) wherein R_(C) is C₁-C₂ alkyl (preferably methyl).

More preferred compounds of the invention are those of Formula I wherein Q₃ is CR₂₁, wherein

R₂₁ is a group of the formula,

X₂ is C substituted with two groups that are independently H or C₁-C₄ alkyl; X₁ is C substituted with H or C₁-C₆ alkyl; Q₁ and Q₂ are independently C substituted with H or C₁-C₆ alkyl; R₇ is O; Y is CR_(C), wherein

R_(C) is —H, methyl, ethyl, trifluoromethyl, or cyclopropyl; R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         n is 1 or 2.

More preferred compounds of the invention are those of Formula I wherein

R₁ and R₂ are independently H or C₁-C₄ alkyl;

Q₁ and Q₂ are both CH;

X₂ is C substituted with two independently selected C₁-C₄ alkyl groups; and

n is 1.

Other preferred compounds of the invention include those having the formula VII,

wherein X₁ and R_(C) are as defined in Formula I; R₅ and R₆ are independently H or C₁-C₄ alkyl; R₁₁ is H or C₁-C₆ alkyl; R_(10a) and R_(10b) are independently H or C₁-C₆ alkyl; R_(9a) and R_(9b) are independently H or C₁-C₆ alkyl; R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         n is 1 or 2.

Preferred compounds of Formula VII include those where

R₁ and R₂ are independently H or C₁-C₄ alkyl;

R_(10a) and R_(10b) are both H; and

R₅ and R₆ are independently C₁-C₄ alkyl.

Other preferred compounds of Formula VII include those

where

X₁ is N.

Other preferred compounds of Formula VII include those where X₁ is CR_(C), wherein R_(C) is hydrogen, methyl, ethyl, cyclopropyl, cyclopropylmethyl, fluoromethyl, difluoromethyl, or trifluoromethyl. In a preferred embodiment of this aspect, the R_(c) group derived from X₁ is hydrogen, methyl, or trifluoromethyl, and the R_(c) group derived from Y carries the definition given in connection with Formula I.

Other preferred compounds of Formula I include those of formula VII,

wherein R_(C) is H, C₁-C₆ alkyl, trifluoromethyl, or cyclopropyl; and R₁-R₆, X₁, and X₄ carry the same definitions as for Formula I.

Preferred compounds of Formula VIII include those where X₁ is N.

Preferred compounds of Formula VIII include those where X₁ is CR_(C), wherein R_(C) is hydrogen, methyl, ethyl, cyclopropyl, cyclopropylmethyl, fluoromethyl, difluoromethyl, or trifluoromethyl. In a preferred embodiment of this aspect, the R_(c) group derived from X₁ is hydrogen, methyl, or trifluoromethyl, and the R_(c) group derived from Y carries the definition given in connection with Formula I.

Preferred compounds of Formula VIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(P)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R_(22r) carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Preferred compounds of Formula VIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Preferred compounds of Formula VIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Other preferred compounds of Formula VIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Other preferred compounds of Formula VIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Other preferred compounds of Formula VIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Still other preferred compounds of Formula VIII are those wherein R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Still other preferred compounds of Formula VIII are those wherein R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Still other preferred compounds of Formula VIII are those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Yet other preferred compounds of Formula VIII are those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring.

Yet other preferred compounds of Formula VIII are those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring; and X₄ is O.

Yet other preferred compounds of Formula VIII are those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring; and X₄ is N—OH.

Other preferred compounds of Formula I are those of Formula IX:

where R₁₁ is hydrogen or methyl, preferably hydrogen; R_(C) is H, C₁-C₂ alkyl, trifluoromethyl, or cyclopropyl; and R₃, R₄, and X₄ carry the same definitions as for Formula I. Preferred compounds of Formula IX include those where R_(C) is C₁-C₂ alkyl, trifluoromethyl, or cyclopropyl.

Preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Preferred compounds of Formula IX include those where R_(C) is methyl, ethyl, trifluoromethyl, or cyclopropyl; R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₂-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Preferred compounds of Formula IX include those where R_(C) is methyl, ethyl, trifluoromethyl, or cyclopropyl; R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Still other preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Still other preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Still other preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Yet other preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Yet other preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Yet other preferred compounds of Formula IX include those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Still other preferred compounds of Formula IX include those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring.

Still other preferred compounds of Formula IX include those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring; and X₄ is O.

Still other preferred compounds of Formula IX include those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring; and X₄ is N—OH.

Preferred compounds of Formulas I-IX include compounds where X₄ is O.

Still other preferred compounds of Formulas I-IX are those where X₄ is N—OH.

Other preferred compounds of Formula I are those where R₂₁ is cyano, R₇ is O, and Y is CR_(C), wherein R_(C) is H, methyl, ethyl, trifluoromethyl, or cyclopropyl.

Other preferred compounds of Formula I are those where, R₂₁ is cyano; R₇ is O; and Y is CR_(C), wherein R_(C) is H, methyl, trifluoromethyl, or cyclopropyl.

Yet other preferred compounds of Formula I are those where R₂₁ is cyano, and X₃ is C substituted with two groups that are independently H or C₁-C₆ alkyl.

More preferred compounds of Formula I are those where R₂₁ is cyano, and Q₁ and Q₂ are independently C substituted with H or C₁-C₆ alkyl.

Yet other preferred compounds of Formula I are those where R₂₁ is cyano, and X₁ is C substituted with H or C₁-C₆ alkyl.

Still other preferred compounds of Formula I are those where R₂₁ is cyano, and X₂ is C substituted with two groups that are independently H or C₁-C₄ alkyl.

In other preferred compounds of Formula I, R₂₁ is cyano, and R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In still other preferred compounds of Formula I, R₂₁ is cyano, and R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In still other preferred compounds of Formula I, R₂₁ is cyano, and R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Other more preferred compounds of Formula I are those where R₂₁ is cyano, and R₄ is H, C₁-C₄ alkyl or halogen.

Particularly preferred compounds of Formula I include those where

-   R₂₁ is cyano, and -   X₂ is C substituted with two groups that are independently H or     C₁-C₄ alkyl; -   X₁ is C substituted with H or C₁-C₆ alkyl; -   Q₁ and Q₂ are independently C substituted with H or C₁-C₆ alkyl; -   X₃ is C substituted with two groups that are independently H or     C₁-C₆ alkyl; -   R₇ is O; -   Y is CR_(C) wherein R_(C) is H or CH₃; and     R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁     is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and     R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms     in the alkyl group are optionally replaced independently by R₂₂,     carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂,     or SO, with the proviso that two O atoms, two S atoms, or an O and S     atom are not immediately adjacent each other,     -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         n is 1 or 2.         Such compounds are referred to herein as compounds of Formula X.

Preferred compounds of Formula X include those where

-   R₁ and R₂ are independently H or C₁-C₄ alkyl; -   Q₁ and Q₂ are both CH; -   X₂ is C substituted with two independently selected C₁-C₄ alkyl     groups; and -   n is 1.

Particularly preferred compounds of Formula I include those where R₂₁ is cyano. Such compounds are referred to hereinafter as compounds of Formula XI.

Preferred compounds of Formula XI are those where R₃ and R₄ are independently halogen or hydrogen.

Preferred compounds of Formula XI are those where R₃ is halogen.

Preferred compounds of Formula XI are those where R₃ is hydrogen and R₄ is halogen.

Preferred compounds of Formula XI are those where R₄ is halogen.

Other preferred compounds of Formula I include those of Formula XII:

R₃ and R₄ are independently halogen or hydrogen, provided that at least one of R₃ and R₄ is halogen, and X₁, R_(C), R₅ and R₆ are as defined for Formula I.

Preferred compounds of Formula XII include those where X₁ is N.

Preferred compounds of Formula XII include those where X₁ is CR_(C), wherein R_(C) is hydrogen, methyl, ethyl, cyclopropyl, cyclopropylmethyl, fluoromethyl, difluoromethyl, or trifluoromethyl.

Preferred compounds of Formula XII are those where R₃ is halogen.

Other preferred compounds of Formula XII are those where R₄ is halogen.

Still other preferred compounds of Formula XII are those where R₃ is fluoro and R₄ is hydrogen or fluoro.

Particularly preferred compounds of Formula XII are those where R₄ is fluoro and R₃ is hydrogen, bromo, or fluoro.

Other particularly preferred compounds of Formula XII are those where R₄ is hydrogen.

Still other preferred compounds of Formula XII are those where R₃ is hydrogen.

Particularly preferred compounds of Formula XII include those where R₃ and R₄ are fluoro.

Preferred compounds of Formula XII are those where R₃ and R₄ are bromo and fluoro respectively.

Yet other preferred compounds of Formula I include those of Formula XII,

wherein R₁-R₆, X₄, X₁, and R_(C) are as defined in Formula I.

Preferred compounds of Formula XIII include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Other preferred compounds of Formula XIII are those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Other preferred compounds of Formula XIII are those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In still other preferred compounds of Formula XIII R₃, R₄ and the carbons to which they are attached form a 6-membered ring.

In more preferred aspects, the previously described preferred embodiments of Formula XIII include compounds wherein X₁ is N or CR_(C), wherein R_(C) is hydrogen, methyl, ethyl, cyclopropyl, cyclopropylmethyl, fluoromethyl, difluoromethyl, or trifluoromethyl.

In more preferred aspects, the previously described preferred embodiments of Formula XIII include compounds wherein X₁ is N.

In more preferred aspects, the previously described preferred embodiments of Formula XIII include compounds wherein X₁ is CR_(C), wherein R_(C) is hydrogen, methyl, ethyl, cyclopropyl, cyclopropylmethyl, fluoromethyl, difluoromethyl, or trifluoromethyl.

Other preferred compounds of Formula I include those of Formula XIV,

wherein R_(C) is —H, —CH₃, —CF₃, or cyclopropyl; and

-   R₃ and R₄ are independently halogen or hydrogen, provided that at     least one of R₃ and R₄ is halogen, and R₅ and R₆ are as defined for     Formula I.

Yet other preferred compounds of Formula II through XIV are those where R₂₁ is cyano; R₇ is O; and Y is CH or C(CH₃).

Yet other preferred compounds of Formula II through XIV are those where R₂₁ is cyano; and R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Yet other preferred compounds of Formula II through XIV are those where R₂₁ is cyano; and R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Yet other preferred compounds of Formula II through XIV are those where R₂₁ is cyano; and R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In another aspect, the invention encompasses compounds of Formula I, wherein Y is CR_(C), wherein R_(C) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, or C₃-C₇ cycloalkyl.

In another aspect, the invention encompasses compounds of Formula I, wherein Y is CH.

In another aspect, the invention encompasses compounds of Formula I, wherein Y is CR_(C), wherein R_(C) is C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, or C₃-C₇ cycloalkyl.

In another aspect, the invention encompasses compounds of Formula I, wherein Y is CR_(C), wherein R_(C) is methyl, ethyl, trifluoromethyl, or cyclopropyl.

In another aspect, the invention encompasses compounds of Formula I, wherein Y is CR_(C), wherein R_(C) is methyl.

In another aspect, the invention encompasses compounds of Formula I, wherein Y is CR_(C), wherein R_(C) is cyclopropyl.

Yet other preferred compounds of Formula I include those of Formula XV,

wherein X₁-X₄, Q₁, Q₂, R_(C), and R₁-R₄ are as defined in Formula I.

Preferred compounds of formula XV are those where Q₁ and Q₂ are each independently hydrogen or C₁-C₆ alkyl.

Other preferred compounds of formula XV are those where R_(c) is C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆ haloalkyl, C₃-C₇cycloalkyl(C₁-C₆)alkyl, or heterocycloalkyl.

More preferred compounds of Formula XV include those where R_(c) is C₃-C₇cycloalkyl, C₁-C₆ haloalkyl, heterocycloalkyl, or C₃-C₇cycloalkyl(C₁-C₆)alkyl.

Particularly preferred compounds of Formula XV include those where R_(c) is C₁-C₃alkyl, C₃-C₅cycloalkyl, C₃-C₅cycloalkyl(C₁-C₃)alkyl, or C₁-C₂ haloalkyl.

Additional preferred compounds of Formula XV include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Other preferred compounds of Formula XV include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Still other preferred compounds of Formula XV are those wherein R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, -halo,         amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl,         —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,         —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy,         C₂-C₁₀ alkynyloxy, mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀         alkyl-Z, or R₂₃.

More preferred compounds of Formula XV are those wherein R₃ and R₄ are independently hydrogen, —N(H)—R₂₂—R_(Z2), wherein

-   -   R_(Z2) is a C₁-C₁₃ alkyl group where up to five of the carbon         atoms in the alkyl group are optionally replaced independently         by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N,         O, S, SO₂, or SO, with the proviso that two O atoms, two S         atoms, or an O and S atom are not immediately adjacent each         other,         -   wherein R_(Z2) is optionally substituted at any available             position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀             alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo,             halo, amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl,             —SO₂—(C₁-C₆)alkyl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl,             —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆             alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or             di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.             Such compounds are referred to herein as compounds of             Formula XVa.

Preferred compounds of Formula XVa are those where X₁ is N.

Preferred compounds of Formula XVa are those where R₂₂ is heteroaryl, aryl, saturated C₃-C₁₀ cycloalkyl, or saturated C₂-C₁₀ heterocycloalkyl.

More preferred compounds of Formula XVa are those where R₂₂ is heteroaryl, aryl, saturated C₃-C₁₀ cycloalkyl, or saturated C₂-C₁₀ heterocycloalkyl; and X₁ is N.

Particularly preferred compounds of Formula XVa are those where R₂₂ is saturated C₃-C₇ cycloalkyl, or saturated C₂-C₆ heterocycloalkyl.

Particularly preferred compounds of Formula XVa are those where R₂₂ is saturated C₃-C₇ cycloalkyl, or saturated C₂-C₆ heterocycloalkyl and X₁ is N.

Preferred compounds of Formula XV are those where X₁ is N. Such compounds are referred to herein as compounds of Formula XVI.

Preferred compounds of Formula XVI include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)_(p)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Preferred compounds of Formula XVI include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and X₄         is O.

Preferred compounds of Formula XVI include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O—, —NH—, —S(O)—, or —S(O)₂NH—, wherein p is 0, 1 or 2; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and X₄         is N—OH.

Other preferred compounds of Formula XVI include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Other preferred compounds of Formula XVI include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and X₄         is O.

Other preferred compounds of Formula XVI include those where R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; and R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and X₄         is N—OH.

Still other preferred compounds of Formula XVI are those wherein R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   wherein R_(Z1) is optionally substituted at any available position     with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl,     hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH,     —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl,     —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy,     C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or     di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

Still other preferred compounds of Formula XVI are those wherein R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is O.

Still other preferred compounds of Formula XVI are those where R₃ and R₄ are independently hydrogen, halo, or —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,

-   -   wherein R_(Z1) is optionally substituted at any available         position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl,         C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino,         cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,         —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl,         —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy,         mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and         X₄ is N—OH.

Yet other preferred compounds of Formula XVI are those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring.

Yet other preferred compounds of Formula XVI are those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring; and X₄ is O.

Yet other preferred compounds of Formula XVI are those where R₃, R₄ and the carbons to which they are attached form a 6-membered ring; and X₄ is N—OH.

Yet other preferred compounds of Formula XVI are those where R₃ and R₄ are both —H.

Yet other preferred compounds of Formula XVI are those where R₃ and R₄ are both —H; and X₄ is O.

Yet other preferred compounds of Formula XVIII are those where R₃ and R₄ are both —H; and X₄ is N—OH.

In another aspect, the invention provides compounds of Formula XXII

Preferred compounds of Formula XXII include those where R_(c) is C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆ haloalkyl, C₃-C₇cycloalkyl(C₁-C₆)alkyl, or heterocycloalkyl.

More preferred compounds of Formula XXII include those where R_(c) is C₃-C₇cycloalkyl, C₁-C₆ haloalkyl, heterocycloalkyl, or C₃-C₇cycloalkyl(C₁-C₆)alkyl, and X₂ is carbon and R₅ and R₆ are C₁-C₆alkyl.

Particularly preferred compounds of Formula XXII include those where R_(c) is C₁-C₃alkyl, C₃-C₅cycloalkyl, C₃-C₅cycloalkyl(C₁-C₃)alkyl, or C₁-C₂ haloalkyl.

Other particularly preferred compounds of Formula XXII include those where R_(c) is methyl, ethyl, cyclopropyl, cyclopropylmethyl, perfluoropropyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoromethyl, perfluoroethyl, or trifluoromethyl.

In a preferred aspect, the invention provides compounds formula I, wherein Q₃ is C—R₂₁.

In a more preferred aspect, the invention provides compounds formula I, wherein Q₃ is C—R₂₁, wherein R₂₁ is cyano.

In more preferred aspect, the invention provides compounds Formula XXIV,

In another preferred aspect, the invention provides compounds formula I, wherein X₁ is N.

In a more preferred aspect, the invention provides compounds

formula I, wherein Q₃ is C—R₂₁, wherein R₂₁ is —C(O)OH, —C(O)—O(C₁-C₆ alkyl), or a group of the formula,

In a another more preferred aspect, the invention provides compounds formula I, wherein Q₃ is C—R₂₁, wherein R₂₁ is a group of the formula,

In a preferred aspect, the invention provides compounds formula XXV,

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N.

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N; and

R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1), wherein

-   -   Z₁ is —O— or —NH—;     -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon         atoms in the alkyl group are optionally replaced independently         by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N,         O, S, SO₂, or SO, with the proviso that two O atoms, two S         atoms, or an O and S atom are not immediately adjacent each         other,         -   wherein R_(Z1) is optionally substituted at any available             position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀             alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo,             halo, amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl,             —SO₂—(C₁-C₆)alkyl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl,             —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆             alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or             di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N; and

-   -   R₄ is H; and     -   R₃ hydrogen, halo, or —Z₁R_(Z1), wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N; and

-   -   R₄ is H; and     -   R₃ is —N(H)R_(Z1), wherein         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N;

-   -   R₄ is H;     -   R₃ is —N(H)R_(Z1), wherein         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and     -   R_(C) is methyl, ethyl, cyclopropyl, cyclopropylmethyl,         fluoromethyl, difluoromethyl, or trifluoromethyl.

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N; and

-   -   R₃ is H; and     -   R₄ is hydrogen, halo, or —Z₁R_(Z1), wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein X₁ is N;

-   -   R₃ is H;     -   R₄ is hydrogen, halo, or —Z₁R_(Z1), wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃;             -   and     -   R_(C) is methyl, ethyl, cyclopropyl, cyclopropylmethyl,         fluoromethyl, difluoromethyl, or trifluoromethyl.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇             cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl.

In a more preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein         -   R₁₁ is hydrogen, halogen, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,             C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, aryl, or             heteroaryl.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl; and     -   R₃ and R₄ are independently hydrogen, halo, or —Z₁R_(Z1),         wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl;     -   R₄ is H; and     -   R₃ hydrogen, halo, or —Z₁R_(Z1), wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl;     -   R₄ is H; and     -   R₃ is —N(H)R_(Z1), wherein         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C″) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl., —C₃-C₇ cycloalkyl,                 -heterocycloalkyl, —C₁-C₆ acyl, -aryl, or -heteroaryl;     -   R₄ is H;     -   R₃ is —N(H)R_(Z1), wherein         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and     -   R_(C) is hydrogen, methyl, ethyl, cyclopropyl,         cyclopropylmethyl, fluoromethyl, difluoromethyl, or         trifluoromethyl.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″), is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl;     -   R₃ is H; and     -   R₄ is hydrogen, halo, or —Z₁R_(Z1), wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.

In a preferred aspect, the invention provides compounds formula XXV, wherein

-   -   X₁ is CR₁₁, wherein     -   R₁₁ is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀         alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇         cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl,         aryl, or heteroaryl, wherein         -   R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein             -   R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇                 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;             -   each R_(CN) is independently —H, —C₁-C₁₀ alkyl,                 —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl,                 —C₁-C₆ acyl, -aryl, or -heteroaryl;     -   R₃ is H;     -   R₄ is hydrogen, halo, or —Z₁R_(Z1), wherein         -   Z₁ is —O— or —NH—;         -   R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the             carbon atoms in the alkyl group are optionally replaced             independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety             selected from N, O, S, SO₂, or SO, with the proviso that two             O atoms, two S atoms, or an O and S atom are not immediately             adjacent each other,             -   wherein R_(Z1) is optionally substituted at any                 available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl,                 C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy,                 carboxamido, oxo, halo, amino, cyano, nitro, —SH,                 —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂,                 —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl,                 —SO—(C₁-C₆)alkyl, —SO₂-aryl, C₁-C₆ alkoxy, C₂-C₁₀                 alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or                 di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃; and     -   R_(C) is hydrogen, methyl, ethyl, cyclopropyl,         cyclopropylmethyl, fluoromethyl, difluoromethyl, or         trifluoromethyl.

In another aspect, the invention encompasses a method of treating cancer comprising administering to a patient in need thereof, a pharmaceutically acceptable amount of a compound or salt of Formula I or a pharmaceutical composition comprising a compound or salt of Formula I.

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for the treatment of cancer, inflammation, or arthritis in a patient in need of such treatment.

In another aspect, the invention encompasses a package comprising a compound or salt of Formula I in a container with instructions on how to use the compound.

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt according of Formula I for the preparation of a medicament for the treatment of a disease or condition related to cell proliferation in a patient in need of such treatment.

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt according of Formula I for the preparation of a medicament for the treatment of a disease or condition related to cell proliferation in a patient in need of such treatment, wherein the disease or condition is cancer, inflammation, or arthritis.

In another aspect, the invention encompasses the use of therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for the treatment of a disease or disorder related to the activity of heat shock protein 90, in a subject in need of such.

In another aspect, the invention encompasses the use of therapeutically effective amount of a compound or salt of Formula I, alone or in combination with another therapeutic agent, for the preparation of a medicament for the treatment of a disease or disorder related to the activity of heat shock protein 90 and/or its client proteins, in a subject in need of such, wherein the HSP-90 mediated disorder is selected from the group of inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases and malignant disease.

In a preferred aspect, the invention encompasses methods for the treatment of cancer in a subject in need of such treatment comprising administration of therapeutically effective amount of a compound or salt of Formula I, in combination with at least one other therapeutic agent.

In a more preferred aspect, the invention encompasses methods for treating cancer in a subject in need of such treatment, the methods comprising administration of therapeutically effective amount of a compound or salt of Formula I, in combination with at least one other anti-cancer agent.

In another preferred aspect, the invention encompasses methods for treating cancer, the methods comprising administration, to a subject in need of such treatment, of a therapeutically effective amount of a compound or salt of Formula I, in combination with radiation therapy.

In another aspect, the invention encompasses the use of therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for the treatment of a fibrogenetic disorder related to the activity of heat shock protein 90, in a subject in need of such, wherein the fibrogenetic disorder is selected from the group of scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis.

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for protecting a subject from infection caused by an organism selected from Plasmodium species.

In a preferred aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for protecting a subject from infection caused by Plasmodium falciparum.

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for reducing the level of infection caused by an organism selected from Plasmodium species in a subject in need of such treatment.

In a preferred aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for reducing the level of infection caused by Plasmodium falciparum in a subject in need of such treatment

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for treating a patient infected with a metazoan parasite.

In a preferred aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I for the preparation of a medicament for treating a patient infected by a metazoan parasite which is Plasmodium falciparum.

In another aspect, the invention encompasses the use of a therapeutically effective amount of a compound or salt of Formula I in combination with one or more known anti-fungal drugs for the preparation of a medicament for treating a patient infected with a fungal infection.

Definitions

The term “alkoxy” represents an alkyl group of indicated number of carbon atoms attached to the parent molecular moiety through an oxygen bridge. Examples of alkoxy groups include, for example, methoxy, ethoxy, propoxy and isopropoxy.

As used herein, the term “alkyl” includes those alkyl groups of a designated number of carbon atoms. Alkyl groups may be straight, or branched. Examples of “alkyl” include methyl, ethyl, propyl, isopropyl, butyl, iso-, sec- and tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, and the like.

The term “alkenyl” as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “alkenoxy” refers to an alkenyl group attached to the parent group through an oxygen atom.

The term “alkynyl” as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

The term “aryl” refers to an aromatic hydrocarbon ring system containing at least one aromatic ring. The aromatic ring may optionally be fused or otherwise attached to other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings. Examples of aryl groups include, for example, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalene and biphenyl. Preferred examples of aryl groups include phenyl, naphthyl, and anthracenyl. More preferred aryl groups are phenyl and naphthyl. Most preferred is phenyl. The aryl groups of the invention may be substituted with various groups as provided herein. Thus, any carbon atom present within an aryl ring system and available for substitution may be further bonded to a variety of ring substituents, such as, for example, halogen, hydroxy, nitro, cyano, amino, C₁-C₈alkyl, C₁-C₈alkoxy, mono- and di(C₁-C₈alkyl)amino, C₃-C₁₀cycloalkyl, (C₃-C₁₀cycloalkyl)alkyl, (C₃-C₁₀cycloalkyl)alkoxy, C₂-C₉heterocycloalkyl, C₁-C₈alkenyl, C₁-C₈alkynyl, halo(C₁-C₈)alkyl, halo(C₁-C₈)alkoxy, oxo, amino(C₁-C₈)alkyl, mono- and di(C₁-C₈alkyl)amino(C₁-C₈)alkyl, C₁-C₈acyl, C₁-C₈acyloxy, C₁-C₈sulfonyl, C₁-C₈thio, C₁-C₈sulfonamido, C₁-C₈aminosulfonyl.

The term “carboxy” as used herein, means a —CO₂H group.

The term “cycloalkyl” refers to a C₃-C₈ cyclic hydrocarbon. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. More preferred are C₃-C₆ cycloalkyl groups. The cycloalkyl groups of the invention may be substituted with various groups as provided herein. Thus, any carbon atom present within a cycloalkyl ring system and available for substitution may be further bonded to a variety of ring substituents, such as, for example, halogen, hydroxy, nitro, cyano, amino, C₁-C₈alkyl, C₁-C₈alkoxy, mono- and di(C₁-C₈alkyl)amino, C₃-C₁₀cycloalkyl, (C₃-C₁₀cycloalkyl)alkyl, (C₃-C₁₀cycloalkyl)alkoxy, C₂-C₉heterocycloalkyl, C₁-C₈alkenyl, C₁-C₈alkynyl, halo(C₁-C₈)alkyl, halo(C₁-C₈)alkoxy, oxo, amino(C₁-C₈)alkyl and mono- and di(C₁-C₈alkyl)amino(C₁-C₈)alkyl.

The terms “halogen” or “halo” indicate fluorine, chlorine, bromine, and iodine.

The term “haloalkoxy” refers to an alkoxy group substituted with one or more halogen atoms, where each halogen is independently F, Cl, Br or I. Preferred halogens are F and Cl. Preferred haloalkoxy groups contain 1-6 carbons, more preferably 1-4 carbons, and still more preferably 1-2 carbons. “Haloalkoxy” includes perhaloalkoxy groups, such as OCF₃ or OCF₂CF₃. A preferred haloalkoxy group is trifluoromethoxy.

The term “haloalkyl” refers to an alkyl group substituted with one or more halogen atoms, where each halogen is independently F, Cl, Br or I. Preferred halogens are F and Cl. Preferred haloalkyl groups contain 1-6 carbons, more preferably 1-4 carbons, and still more preferably 1-2 carbons. “Haloalkyl” includes perhaloalkyl groups, such as CF₃ or CF₂CF₃. A preferred haloalkyl group is trifluoromethyl.

The term “heterocycloalkyl” refers to a ring or ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein said heteroatom is in a non-aromatic ring. The heterocycloalkyl ring is optionally fused to or otherwise attached to other heterocycloalkyl rings and/or non-aromatic hydrocarbon rings and/or phenyl rings. Preferred heterocycloalkyl groups have from 3 to 7 members. More preferred heterocycloalkyl groups have 5 or 6 members. Examples of heterocycloalkyl groups include, for example, 1,2,3,4-tetrahydroisoquinolinyl, piperazinyl, morpholinyl, piperidinyl, tetrahydrofuranyl, pyrrolidinyl, pyridinonyl, and pyrazolidinyl. Preferred heterocycloalkyl groups include piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, pyridinonyl, dihydropyrrolidinyl, and pyrrolidinonyl. The heterocycloalkyl groups of the invention may be substituted with various groups as provided herein. Thus, any atom present within a heterocycloalkyl ring and available for substitution may be further bonded to a variety of ring substituents, such as, for example, halogen, hydroxy, nitro, cyano, amino, C₁-C₈alkyl, C₁-C₈alkoxy, mono- and di(C₁-C₈alkyl)amino, C₃-C₁₀cycloalkyl, (C₃-C₁₀cycloalkyl)alkyl, (C₃-C₁₀cycloalkyl)alkoxy, C₂-C₉heterocycloalkyl, C₁-C₈alkenyl, C₁-C₈alkynyl, halo(C₁-C₈)alkyl, halo(C₁-C₈)alkoxy, oxo, amino(C₁-C₈)alkyl and mono- and di(C₁-C₈alkyl)amino(C₁-C₈)alkyl.

The term “heteroaryl” refers to an aromatic ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur. The heteroaryl ring may be fused or otherwise attached to one or more heteroaryl rings, aromatic or non-aromatic hydrocarbon rings or heterocycloalkyl rings. Examples of heteroaryl groups include, for example, pyridine, furan, thienyl, 5,6,7,8-tetrahydroisoquinoline and pyrimidines. The heteroaryl groups of the invention may be substituted with various groups as provided herein. Thus, any carbon atom present within an heteroaryl ring system and available for substitution may be further bonded to a variety of ring substituents, such as, for example, halogen, hydroxy, nitro, cyano, amino, C₁-C₈alkyl, C₁-C₈alkoxy, mono- and di(C₁-C₈alkyl)amino, C₃-C₁₀cycloalkyl, (C₃-C₁₀cycloalkyl)alkyl, (C₃-C₁₀cycloalkyl)alkoxy, C₂-C₉heterocycloalkyl, C₁-C₈alkenyl, C₁-C₈alkynyl, halo(C₁-C₈)alkyl, halo(C₁-C₈)alkoxy, oxo, amino(C₁-C₈)alkyl and mono- and di(C₁-C₈alkyl)amino(C₁-C₈)alkyl.

Preferred examples of heteroaryl groups include thienyl, benzothienyl, pyridyl, quinolyl, pyrazolyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, dibenzofuranyl, thiazolyl, benzothiazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, benzisothiazolyl, triazolyl, pyrrolyl, indolyl, pyrazolyl, and benzopyrazolyl.

The compounds of this invention may contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates, chiral non-racemic or diastereomers. In these situations, the single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis or by resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent; chromatography, using, for example a chiral HPLC column; or derivatizing the racemic mixture with a resolving reagent to generate diastereomers, separating the diastereomers via chromatography, and removing the resolving agent to generate the original compound in enantiomerically enriched form. Any of the above procedures can be repeated to increase the enantiomeric purity of a compound.

When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, it is intended that the compounds include the cis, trans, Z- and E-configurations. Likewise, all tautomeric forms are also intended to be included.

Pharmaceutical Compositions

The compounds of general Formula I may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a compound of general Formula I and a pharmaceutically acceptable carrier. One or more compounds of general Formula I may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing compounds of general Formula I may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques. In some cases such coatings may be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Formulations for oral use may also be presented as lozenges.

Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of general Formula I may also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.

Compounds of general Formula I may be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base.

Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.

Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The antiinflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

For administration to non-human animals, the composition may also be added to the animal feed or drinking water. It may be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It may also be convenient to present the composition as a premix for addition to the feed or drinking water. Preferred non-human animals include domesticated animals.

The compounds of the present invention may be administered alone or in combination with at least one additional therapeutic agent or therapy, e.g., radiation therapy, to a patient in need of such treatment. The additional therapeutic agent or therapy may be administered at the same time, separately, or sequentially with respect to the administration of a compound of the invention. Such additional therapeutic agents included, but are not limited to, anti-cancer agents, anti-inflammatory agents, and the like.

The compounds of the present invention may be prepared by use of known chemical reactions and procedures. Representative methods for synthesizing compounds of the invention are presented below. It is understood that the nature of the substituents required for the desired target compound often determines the preferred method of synthesis. All variable groups of these methods are as described in the generic description if they are not specifically defined below.

Methods of Preparation

General Procedure

Representative synthetic procedures for the preparation of compounds of the invention are outlined below in following schemes. Unless otherwise indicated, X₁, X₂, X₃, n, R₅, R₆, R₇, R_(C), R₁₁, and Y carry the definitions given in connection with Formula I. The definition of R is as set forth above in connection with Formula XVII.

Those having skill in the art will recognize that the starting materials and reaction conditions may be varied, the sequence of the reactions altered, and additional steps employed to produce compounds encompassed by the present invention, as demonstrated by the following examples. In some cases, protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general, the need for such protecting groups as well as the conditions necessary to attach and remove such groups will be apparent to those skilled in the art of organic synthesis.

The disclosures of all articles and references mentioned in this application, including patents, are incorporated herein by reference in their entirety.

EXAMPLES

The preparation of the compounds of the invention is illustrated further by the following examples, which are not to be construed as limiting the invention in scope or spirit to the specific procedures and compounds described in them. In all cases, unless otherwise specified, the column chromatography is performed using a silica gel solid phase.

Example 1

3,6,6-Trimethyl-1,5,6,7-tetrahydro-indol-4-one (Compound 1)

To a solution of anti-pyruvic aldehyde-1-oxime (10 g, 1 eq) and 5,5-dimethyl-1,3-cyclohexanedione (16.1 g, 1 eq) in HOAc—H₂O (7:3, 200 mL) was added zinc powder (14.95 g, 2 eq) slowly with cooling by a water bath at room temperature. The mixture then was refluxed overnight, concentrated to dryness, partitioned between brine (300 mL) and dichloromethane (300 mL). The pH was adjusted to ca. 6 with saturated aqueous NaHCO₃, then the mixture was extracted with dichloromethane (3×200 mL). The organic layers were combined, dried over Na₂SO₄, filtered, concentrated. The crude product was purified by flash chromatography eluting with 5% ethyl acetate in dichloromethane. The combined organic fractions were concentrated, triturated in ether-hexane (2:1) for 1 hour, then filtered, washed with hexane to give the pure title compound (9 g, 45% yield) as a solid. LCMS m/z: (M+H)=178.1.

Example 2

2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile (Compound 2)

The title compound of Example 1 (9.8 g, 55.3 mmol) and 2-bromo-4-fluorobenzonitrile (13.27 g, 66.4 mmol) were dissolved in anhydrous dimethylformamide (DMF, 300 mL). To this was added sodium hydride (95%, 2.79 g, 111 mmol) and the reaction was stirred at 55° C. for 1 hour. The reaction mixture was cooled to room temperature and water was added. A tan solid precipitated which was filtered, washed with water and ether and then dried in vacuo (16.5 g, 84%). LCMS m/z: (M+H)=358.1.

Example 3

2-(trans-4-Hydroxy-cyclohexylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 3)

A “Personal Chemistry” microwave vial was charged with the title compound of Example 2 [2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile (1.072 g, 3.0 mmol)], trans-4-aminocyclohexanol (1.382 g, 12.0 mmol), palladium (II) acetate (33.7 mg, 5 mol %), 1,1′-bis(diphenylphosphino)ferrocene (DPPF) (166.3 mg, 10 mol %), and sodium tert-butoxide (576.7 mg, 6.0 mmol). To this was added toluene (20 mL) and the reaction was heated with microwave irradiation to 115° C. for 15 min. After allowing the reaction vessel to cool, a suspension formed and was filtered and the filtrate evaporated. The residue was purified by flash chromatography. The intermediate product was hydrolyzed by dissolution in 25% dimethylsulfoxide/ethanol, adding 0.5 mL of 1 N sodium hydroxide and 0.5 mL of 30% aqueous hydrogen peroxide, followed by stirring at room temperature for 4 hours. After judging the reaction to be complete by TLC, the DMSO/ethanol mixture was diluted with water and extracted with ethyl acetate (3×). The combined organics were washed with brine (2×), dried over Na₂SO₄, and evaporated. The compound was purified by column chromatography eluting with EtOAc-MeOH to yield 575 mg (47% yield) of the title compound as a white powder. LCMS m/z: (M+H)=410.3

Example 4

2-(Tetrahydro-pyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 4)

A “Personal Chemistry” microwave vial was charged with the title compound of Example 2 (2.858 g, 8.0 mmol), 4-aminotetrahydropyran (3.236 g, 32.0 mmol), palladium (II) acetate (89.8 mg, 5 mol %), 1,1′-bis(diphenylphosphino)ferrocene (443.6 mg, 10 mol %), and sodium tert-butoxide (1.538 g, 16.0 mmol). The reagents were suspended in toluene (40 mL) and were heated with microwave radiation to a temperature of 115° C. for fifteen minutes. After allowing the reaction vessel to cool, the suspension was filtered and the filtrate concentrated. After purifying the crude intermediate nitrile by flash chromatography, the nitrile was dissolved in 25% dimethylsulfoxide/ethanol, and 2 mL of 1 N sodium hydroxide and 2 mL of 30% aqueous hydrogen peroxide were added, followed by stirring at room temperature for 16 hours. The DMSO/ethanol mixture was then diluted with water and extracted with ethyl acetate (3×). The combined organics were washed with brine (2×), dried over Na₂SO₄, and evaporated. The residue was purified by column chromatography (EtOAc/MeOH) to yield 1.132 g (36%) of the title compound as an off-white powder. LCMS m/z: (M+H)=396.7.

Example 5

2-(2-Methoxy-ethylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 5)

A “Personal Chemistry” microwave vial was charged with the title compound of Example 2 (107.1 mg, 0.3 mmol), 2-methoxyethylamine (91.3 mg, 1.2 mmol), palladium (II) acetate (3.4 mg, 5 mol %), 1,1′-bis(diphenylphosphino)ferrocene (16.6 mg, 10 mol %), and sodium tert-butoxide (57.7 mg, 0.6 mmol). The reagents were suspended in toluene (2 mL) and were heated with microwave radiation to a temperature of 115° C. for fifteen minutes. After allowing the reaction vessel to cool, the suspension was filtered and the filtrate evaporated. After purifying the crude intermediate nitrile by flash chromatography, hydrolysis was performed by dissolving the residue in 25% dimethylsulfoxide/ethanol, adding 5 drops of 1 N sodium hydroxide and 5 drops of 30% aqueous hydrogen peroxide, followed by stirring at room temperature for 3 hours. The DMSO/ethanol mixture was then diluted with water and extracted with CH₂Cl₂ (3×). The combined organics were washed with brine (2×), dried over Na₂SO₄, and concentrated. The compound was purified by column chromatography (hexane/EtOAc) to yield the title compound (94.4 mg, 85% yield) of an off-white powder. LCMS m/z: (M+H) 370.2.

Example 6

2-(3,4,5-Trimethoxy-phenylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 6)

A “Personal Chemistry” microwave vial was charged with the title compound of Example 2 (107.1 mg, 0.3 mmol), 3,4,5-trimethoxyaniline (219.9 mg, 1.2 mmol), palladium (II) acetate (3.4 mg, 5 mol %), 1,1′-bis(diphenylphosphino)ferrocene (16.6 mg, 10 mol %), and sodium tert-butoxide (57.7 mg, 0.6 mmol). The reagents were suspended in toluene (2 mL) and were heated with microwave radiation to a temperature of 115° C. for fifteen minutes. After allowing the reaction vessel to cool, the suspension was filtered and the filtrate evaporated. The residue was purified by flash chromatography, and hydrolysis was performed by dissolving the product in 25% dimethylsulfoxide/ethanol, adding 5 drops of 1 N sodium hydroxide and 5 drops of 30% aqueous hydrogen peroxide, followed by stirring at room temperature for 3 hours. The DMSO/ethanol mixture was then diluted with water and extracted into EtOAc (3×). The combined organics were washed with brine (2×), dried over Na₂SO₄, and concentrated. The compound was purified by column chromatography (hexane/EtOAc) to yield 28.4 mg (20%) of the title compound as a yellow powder. LCMS m/z: (M+H) 478.3

Example 7

2-[(Pyridin-3-ylmethyl)-amino]-4-(3,6,6-trimethyl-4-ox-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 7)

A “Personal Chemistry” microwave vial was charged with the title compound of Example 2 (107.1 mg, 0.3 mmol), 3-(aminomethyl)pyridine (129.8 mg, 1.2 mmol), palladium (II) acetate (3.4 mg, 5 mol %), 1,1′-bis(diphenylphosphino)ferrocene (16.6 mg, 10 mol %), and sodium tert-butoxide (57.7 mg, 0.6 mmol). The reagents were suspended in toluene (2 mL) and were heated with microwave radiation to a temperature of 125° C. for fifteen minutes. The crude intermediate nitrile was purified by flash chromatography (hexane/EtOAc) chromatography. Hydrolysis was performed by dissolving the residue in 25% dimethyl sulfoxide/ethanol, adding 4 drops of 1 N sodium hydroxide and 4 drops of 30% aqueous hydrogen peroxide, and stirring at room temperature for 15 minutes. The DMSO/ethanol mixture was then diluted with water and extracted into EtOAc (3×). The combined organics were washed with brine (2×), dried over Na₂SO₄, and concentrated. The compound was purified by column chromatography (hexane/EtOAc) to yield 50 mg (41%) of the title compound as a yellow powder. LCMS m/z: (M+H) 403.

Example 8

2-(4-oxo-cyclohexylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 8)

The title compound of Example 3 [2-(4-Hydroxy-cyclohexylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide](150 mg, 0.366 mmol) and Dess-Martin periodinane (0.366 mmol) were dissolved in anhydrous CH₂Cl₂ and stirred at room temperature for one hour. The reaction mixture was concentrated and the title compound was isolated as a white solid (36.2 mg, 24% yield) after purification by column chromatography eluting with EtOAc-MeOH. LCMS m/z: (M+H)=408.3.

Example 9

2-[trans-4-(2-Morpholin-4-yl-ethoxy)-cyclohexylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (Compound 9)

A microwave reaction vial was charged with the title compound of Example 3 [2-(trans-4-Hydroxy-cyclohexylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide](100 mg, 0.244 mmol), 4-(2-chloroethyl)morpholine hydrochloride (45.4 mg, 0.244 mmol), sodium hydride (17.3 mg, 0.732 mmol), and a catalytic amount of potassium iodide. After suspending in DMF, the reaction mixture was heated to 180° C. in the “Personal Chemistry” microwave for eight minutes. The solution was then diluted with water and extracted into EtOAc (2×). The organic layers were extracted with 2N HCl (2×). The aqueous extracts basified with aqueous sodium hydroxide, and were extracted with EtOAc (3×). The combined organics were dried over Na₂SO₄, concentrated, and purified by column chromatography (EtOAc/MeOH) to yield the title compounds as a white solid. LCMS m/z: (M+H) 523.9.

Example 10

3-bromo-4-cyanophenylhydrazine (Compound 10)

In a clean, dry 250-mL round-bottom flask, 2-bromo-4-fluorobenzonitrile (25.34 g) was dissolved in tetrahydrofuran (50 mL) under N₂. To this was slowly added anhydrous hydrazine (50 mL). The solution color changed from yellow to red-orange. The reaction was allowed to stir at room temperature for 16 hours. A yellow-white crystalline solid precipitated from the solution. The mixture was then diluted with THF (50 mL) to dissolve the solids. The organic layer was then washed with saturated sodium bicarbonate solution until the pH of the organic layer was approximately 8.5. The organic layer was isolated and the solvent was removed under reduced pressure to give a white solid. This was place in a fritted glass funnel and washed with 1.5 L of water, followed by of diethyl ether (ca. 200 mL). The ether wash was then combined with the white solid and dried under reduced pressure. The title compound was isolated as a fluffy, white or off-white solid (23.43 g, 87.2% yield). LCMS m/z: calculated=212.05; observed=252.98 (M+H+ acetonitrile).

Example 11

2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (Compound 11)

In a clean, dry 20 mL microwave reaction vial, the title compound of Example 10 (2.49 g) was combined with 2-acetyl-5,5-dimethyl-1,3-cyclohexanedione (2.14 g). The contents of the vial were dissolved in ethanol-acetic acid (12 mL, 3:1). The vial was sealed and agitated on a vortex. The vial was then placed in the microwave reactor and heated to 150° C. for 15 min. The vial was then cooled then placed in the refrigerator for 1 hour. The cooled solution was then diluted with water (8 mL) and poured onto a fritted glass funnel. The orange solid was washed with H₂O (100 mL) followed by ethanol (25 mL). The solid was then dried under reduced pressure. The title compound was obtained as of a light-orange crystalline solid (3.7463 g, 88.85% yield). LCMS m/z M+H=358.1.

Example 12

2-(Tetrahydro-pyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 12)

The title compound of Example 11 (100 mg, 0.28 mmol), Pd(OAc)₂ (3.2 mg, 5 mol %), DPPF (15.5 mg, 10 mol %) and NaOtBu (54 mg, 0.56 mmol) were added to a 2 mL microwave vial. Toluene (0.5 mL) and 4-aminotetrahydropyran (56 μL, 0.56 mmol) were added and the vial was evacuated and back-filled with N₂. The reaction mixture was heated at 120° C. for 15 min (microwave). The reaction mixture was filtered and the solids washed with methylene chloride. The product was purified using flash chromatography eluting with hexanes and ethyl acetate. Product was recovered as an off-white solid (88 mg, 83%), LCMS m/z: (M+H)=379.3. Ethanol (0.8 mL), DMSO (0.2 mL), NaOH (5 N, 93 μL, 2 mol eq) and H₂O₂ (0.1 mL, 30% solution in H₂O) were added to the pyrazole (88 mg, 0.23 mmol) in a 2 mL microwave vial. The reaction mixture was heated at 100° C. for 10 min. Product was recovered by washing with H₂O and ethyl acetate. Solvent was removed in vacuo to yield the title compound as a yellow solid (88 mg, 100%), LCMS m/z: (M+H)=397.3.

Example 13

2-(Tetrahydrothiopyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)benzamide (Compound 13)

Tetrahydro-thiopyran-4-one (10.0 g, 86.0 mmol) and NH₄OAc (60 g, 10 mole eq) were dissolved in 200 mL of MeOH/H₂O (1:1). To this was added NaCNBH₃ (10.8 g, 172.0 mmol) and the reaction mixture was allowed to stir at room temperature overnight. Methanol was removed under vacuum and the product was extracted from the aqueous layer with ethyl acetate (3×100 mL) and washed with brine. The organic layer was washed with 10% aqueous HCl (150 mL) that was then basified with 10% NaOH solution (to pH 11). The basic solution was then washed with ethyl acetate and dried over MgSO₄, to give 4-aminotetrahydrothiopyran which was used without further purification, LCMS m/z: (M+H)⁺=118.2. Compound 11 (1.4 g, 3.9 mmol), Pd(OAc)₂ (44.7 mg, 5 mol %), DPPF (229 mg, 10 mol %) and NaOtBu (790 mg, 7.8 mmol) were added to a 20 mL microwave vial. Toluene (12 mL) and 4-aminotetrahydrothiopyran (550 mg, 1.2 mol eq) were added and the vial was evacuated and back-filled with N₂. The reaction mixture was heated at 130° C. for 20 min (microwave). The reaction mixture was filtered and the solids washed with CH₂Cl₂. The product was purified using flash chromatography eluting with Hexanes and Ethyl acetate. The product, 2-(tetrahydro-thiopyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile, was recovered as a off-white solid (350 mg), LCMS m/z (M+H)⁺=395.3.

The preceeding product (830 mg, 2.1 mmol) was dissolved in ethanol (12 mL) and DMSO (3 mL) to which NaOH (5 N, 841 μL, 2 mol eq) was added. The reaction mixture was heated at 70° C. overnight. The reaction mixture was washed with H₂O and EtOAc. The product was purified by flash chromatography eluting with Hexanes and Ethyl acetate. The title compound was obtained as an off-white solid (490 mg), LCMS m/z (M+H)⁺ =413.2

Example 14

2-(1-Oxo-hexahydro-1-Tetrahydrothiopyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)benzamide (Compound 14)

2-(Tetrahydrothiopyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo4,5,6,7-tetrahydroindazol-1-yl)benzamide was dissolved in ethanol to which H₂O₂ (a few drops of 30% solution in H₂O) was added. The reaction mixture was allowed to stir at rt for 30 min. Product was isolated via extraction with EtOAc and H₂O. The title compound was obtained as an off-white solid (20 mg), LCMS m/z (M+H)⁺=429.2

Example 15

2-(1,1-Dioxo-hexahydro-1-Tetrahydrothiopyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)benzamide (Compound 15)

2-(Tetrahydrothiopyran-4-ylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindazol-1-yl)benzamide (25 mg, 0.063 mmol) was dissolved in a mixture of ethanol (1 mL) and DMSO (0.25 mL) to which NaOH (5 N, 25 μL, 2 mol eq) and H₂O₂ (excess, 30% solution in H₂O) was added. The reaction mixture was heated at 70° C. overnight. The reaction mixture was washed with H₂O and EtOAc. The product was purified using flash chromatography eluting with dichloromethane and methanol. The title compound was obtained as an off-white solid (20 mg), LCMS m/z (M+H)⁺=445.2

Example 16

6,6-Dimethyl-3-trifluoromethyl-1,5,6,7-tetrahydro-indazol-4-one (Compound 16)

A mixture of 5,5-dimethyl-1,3-cyclohexandione (7.0 g, 49.9 mmol, 1.0 equiv), p-toluenesulfonylhydrazide (9.3 g, 49.9 mmol, 1.0 eq.), and p-toluenesulfonic acid (100 mg, 0.53 mmol, 0.01 eq.) in 300 mL of toluene was heated at reflux. After 30 minutes the reaction mixture was cooled, and 50 mL of toluene was added to the reaction mixture. The reaction was returned to heating at reflux. After 1 hour the reaction mixture was cooled to ambient temperature. The solids were collected by filtration, washed three times with ether, and dried under vacuum to afford 3,3-dimethyl-5-(p-tolylsulfonylhydrazono)-cyclohexanone (14.26 g, 93%) as a light yellow solid: LC/MS (m/z) [M+H]⁺=309.1.

To a solution/suspension of 3,3-dimethyl-5-(p-tolylsulfonylhydrazono)-cyclohexanone (4.0 g, 12.97 mmol, 1.0 eq.) in 72 ml of tetrahydrofuran and 24 mL of triethylamine was added trifluoroacetic anhydride (1.8 mL, 12.97 mmol, 1.0 eq.). The dark red reaction mixture was heated at 55° C. After 15 min the reaction mixture was homogeneous. After 2 h the reaction mixture was cooled to ambient temperature. Methanol (16 mL) and a 1:1 solution of water-1 M aqueous sodium hydroxide (16 mL) were added. After stirring for 3 h, the reaction mixture was diluted with 50 mL of saturated aqueous ammonium chloride and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was filtered through a plug of silica gel, eluting with ethyl acetate. The filtrate was concentrated in vacuo, and the residue was treated with ether. The solids were collected by filtration and washed with ether. The filtrate was concentrated in vacuo, and the resulting residue was treated with ether. The solids were collected by filtration, washed with ether, and combined with the initial solids to provide 6,6-dimethyl-3-trifluoromethyl-1,5,6,7-tetrahydro-indazol-4-one (1.24 g, 41%) as a reddish orange solid: LC/MS (m/z): [M+H]⁺233.1.

Example 17

2-bromo-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (Compound 17)

Sodium hydride (168 mg, 7.02 mmol, 1.0 eq.) was added to a solution of 6,6-dimethyl-3-trifluoromethyl-1,5,6,7-tetrahydro-indazol-4-one (1.63 g, 7.02 mmol, 1.0 eq.) in 35 mL of anhydrous dimethyl sulfoxide. After 15 min 2-bromo-4-fluorobenzonitrile (2.25 g, 11.23 mmol, 1.6 eq.) was added as a solid. The reaction mixture was heated at 45° C. After 23 h the reaction mixture was cooled to ambient temperature and quenched with 10 mL of saturated aqueous ammonium chloride. The mixture was diluted with water and extracted with ethyl acetate (4×). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified on a Biotage (SiO₂, hexanes-ethyl acetate) to afford 2-bromo-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (1.83 g, 63%) as an off-white powder, LC/MS: (M+H)=412.0.

Example 18

2-(Cyclopent-3-enylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)benzamide (Compound 18)

1-(2-Bromo-4-cyanophen-4-yl)-3,6,6-trimethyltetrahydroindazal-4-one (2.0 g, 5.6 mmol), Pd(OAc)₂ (64 mg, 5 mol %), DPPF (328 mg, 10 mol %) and NaOtBu (1.13 mg, 11.2 mmol) were added to a 20 mL microwave vial. Toluene (15 mL) and 1-amino-3-cyclopentene (11.2 mmol) were added and the vial was evacuated and back-filled with N₂. The reaction mixture was heated at 120° C. for 15 minutes. The reaction mixture was filtered and the solids washed with CH₂Cl₂. The product was purified using flash chromatography eluting with hexanes and ethyl acetate. Product was obtained as an off-white solid (1.35 g), LCMS m/z (M+H)⁺=361.2.

The preceeding product (2.71 g, 7.5 mmol) was dissolved in ethanol (20 mL) and DMSO (5 mL), and NaOH (5 N, 2.51 mL, 2 mol eq) and H₂O₂ (3.0 mL, 30% solution in H₂O) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was washed with H₂O and extracted with EtOAc. The product was purified using flash chromatography eluting with hexanes and ethyl acetate. The title compound was obtained as an off-white solid (490 mg), LCMS m/z: (M+H)⁺ =379.2

Example 19

4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide (Compound 19)

Sodium tert-butoxide (269 mg, 2.80 mmol, 2.0 equiv) was added to a stirred solution/suspension of 2-bromo-4-(6,6-dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (500 mg, 1.40 mmol, 1.0 eq.), 3,4,5-trimethoxyaniline (513 mg, 2.80 mmol, 2.0 eq.), palladium (II) acetate (16 mg, 0.07 mmol, 0.05 eq.), and 1,1′-bis(diphenylphosphino)ferrocene (78 mg, 0.14 mmol, 0.10 eq.) in 3.75 mL of toluene. The reaction vial was capped, and the reaction mixture was heated 20 minutes at 120° C. under microwave irradiation. The individual reaction mixtures were diluted with ethyl acetate, combined, and partitioned with water. The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified on a Biotage System (SiO₂, hexanes-ethyl acetate) to afford 4-(6,6-dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzonitrile (1.59 g, 82%) as a tan solid: LC/MS (m/z): [M+H]⁺ 461.9.

To a mixture of 4-(6,6-dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzonitrile (1.56 g, 3.39 mmol, 1.0 eq.) in 17 mL of a mixture of 4:1 ethanol-dimethyl sulfoxide was added 2 mL of 1 M aqueous sodium hydroxide and 2 mL of 30% hydrogen peroxide. After 3 hours the reaction mixture was diluted with water and extracted with ethyl acetate (3×). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound, 4-(6,6-dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide, (1.61 g, 99%) as a tan solid: LC/MS (m/z): [M+H]⁺ 479.3.

Example 20

Amino-acetic acid trans-4-[2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-phenylamino]-cyclohexyl ester; methanesulfonic acid salt (Compound 20)

2-(trans-4-Hydroxy-cyclohexylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzamide (750.0 mg, 1.832 mmol), N-(tert-butoxycarbonyl)glycine (641.8 mg, 3.664 mmol, 2.0 eq.), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (702.4 mg, 3.664 mmol, 2.0 eq.) and a catalytic amount of 4-dimethylaminopyridine were dissolved in 20 mL of CH₂Cl₂ and stirred at room temperature for sixteen hours. The solvent was removed in vacuo, and the residue purified by column chromatography (eluting with EtOAc), yielding 780.5 mg (75.2% yield) of a Boc protected pale yellow foam.

The preceeding product was dissolved in 15 mL of CH₂Cl₂ and cooled to 0° C. in an ice bath. 15 mL of trifluoroacetic acid was then added and the reaction mixture stirred at 0° C. for 5 minutes and 30 minutes at room temperature. The trifluoroacetic acid and CH₂Cl₂ were removed in vacuo, and the residue dissolved in water. The aqueous solution was basified by addition of saturated aqueous sodium bicarbonate. The aqueous suspension was extracted with EtOAc (3×), and the combined organics washed with water and dried over Na₂SO₄. Removal of the solvent in vacuo yielded 569.7 mg (66.6% yield through coupling and deprotection) of an off-white foam, which by LC/MS showed pure product (m/z: (M+H)=467.3). This free base was then converted to the mesylate salt by dissolution in CH₂Cl₂, and adding one equivalent dropwise of methanesulfonic acid, followed by stirring at room temperature for 1 hour. Removal of the solvent in vacuo yielded 680.7 mg of the title compound as an off-white powder.

Example 21

Dimethylamino-acetic acid trans-4-[2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-phenylamino]-cyclohexyl ester; methanesulfonic acid salt (Compound 21)

The procedure of Example 20 was used, substituting dimethylamino-acetic acid for N-(tert-butoxycarbonyl)glycine to give the title compound. LCMS m/z: (M+H)=495.2.

Example 22

2-[3-(2-Dimethylamino-ethoxy)-4-methoxy-phenylamino]-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 22)

To a solution of 2-methoxy-5-nitro-phenol (10 g), (2-chloro-ethyl)-dimethyl-amine hydrochloride (9.37 g) in dimethylformamide (150 mL) was added NaH (2.98 g) slowly under N₂ and at room temperature. The mixture was then stirred at 140° C. heating with an oil bath for 5 hours. The reaction was concentrated to dryness, dissolved in 2 M HCl (200 mL) and washed with ethyl acetate (2×100 mL). The aqueous layer was basified with K₂CO₃, extracted with dichloromethane (3×200 mL) and ethyl acetate (2×100 mL), dried over Na₂SO₄, filtered, concentrated to give [2-(2-Methoxy-5-nitro-phenoxy)-ethyl]-dimethylamine (9.17 g, 65% yield). LCMS (m/z) M+H: 241.1.

The preceding product (10.53 g) and 10% Pd/C (1 g) were mixed with EtOH (200 mL) and hydrogenated at 50 psi overnight. The reaction mixture was filtered through a Celite plug, and the filter cake was washed with MeOH. The filtrate was concentrated to dryness to give 3-(2-dimethylamino-ethoxy)-4-methoxy-phenylamine (9.05 g, 98% yield). LCMS (m/z) M+H: 211.2.

2-bromo-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (500 mg, 1 eq), 3-(2-dimethylamino-ethoxy)-4-methoxy-phenylamine (306 mg, 1.2 eq), Pd(OAc)₂ (14 mg), DPPF (66 mg), and NaOtBu (214 mg, 2 eq) were mixed in toluene (5 mL) and microwaved at 140° C. for 25 minutes. Then 10 mL of EtOH (4)/H₂O (l) were added, followed by NaOH (700 mg, 2 eq) and H₂O₂ (1 mL). The mixture was microwaved at 100° C. for 15 min, then concentrated to dryness, and purified by flash chromatography, eluting with 20% EtOH in dichloromethane to give the title compound (480 mg, 71% two-step yield). LCMS (m/z): M+H=560.3.

Example 23

4-(6,6-Dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (Compound 23)

4-Aminotetrahydropyran (245 mg, 2.42 mmol, 2.0 eq) and sodium tert-butoxide (233 mg, 2.42 mmol, 2.0 eq) were added to a stirred solution/suspension of 2-bromo-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (500 mg, 1.21 mmol, 1.0 eq), palladium (II) acetate (14 mg, 0.06 mmol, 0.05 eq), and DPPF (67 mg, 0.12 mmol, 0.10 eq) in 3.75 mL of toluene. The reaction vial was capped, and the reaction mixture was heated 20 minutes at 120° C. under microwave irradiation. The reaction mixture was diluted with water and ethyl acetate and combined. The layers were separated, and the aqueous layer was extracted with ethyl acetate (3×). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified on a Biotage system (SiO₂, hexanes-ethyl acetate) to afford 4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzonitrile (772 mg, 49%) as a tan solid: LC/MS (m/z): [M+H]⁺ 433.7. Further elution with ethyl acetate afforded 4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (713 mg, 44%) as a yellow solid: LC/MS (m/z): [M+H]⁺ 451.2.

To a solution/suspension of 4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzonitrile (772 mg, 1.79 mmol, 1.0 eq) in 10 mL of 4:1 ethanol-dimethyl sulfoxide was added 1 mL of 1 M aqueous sodium hydroxide and 1 mL of 30% hydrogen peroxide. After 30 minutes the reaction mixture was diluted with water and extracted with ethyl acetate (4×). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound, 4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (788 mg, 98%) as a tan solid: LC/MS (m/z): [M+H]⁺ 451.2.

Example 24

3-Difluoromethyl-6,6-dimethyl-1,5,6,7-tetrahydro-indazol-4-one (Compound 24)

A mixture of 5,5-Dimethyl-cyclohexane-1,3-dione (10 g), p-toluenesulfonylhydrazide (13.3 g) p-toluesulfonic acid (140 mg) in toluene (450 mL) was refluxed for 0.5 h. Then 100 mL of toluene was added and the mixture was refluxed for another 1 h. The mixture was cooled to room temperature, filtered, the solids were washed by ether (3×200 mL), and dried completely to give the hydrazone as a solid (20.4 g, 92.7%). LCMS M+H, 309.1 (MW: 308). It was used in the next step without further purification.

The preceeding product (8.86 g) was dissolved in a mixture of tetrahydrofuran (100 mL) and triethylamine (30 mL), placed under N₂, and difluoroacetic anhydride (5 g) was added slowly while swirling, then the mixture was heated to 55° C. overnight. The mixture was cooled to room temperature, and MeOH (35.5 mL) was added, followed by 35.5 mL of a 1:1 mixture of H₂O and 1 N NaOH. This mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with saturated aqueous NH₄Cl (120 mL), extracted with ethyl acetate (4×150 mL), dried over Na₂SO₄, filtered, concentrated, purified by column chromatography eluting with a 1:1 mixture of ethyl acetate and hexanes to give 3-difluoromethyl-6,6-dimethyl-1,5,6,7-tetrahydro-indazol-4-one (3.12 g, 50.6%). LCMS (M+H): 215.1 (MW: 214).

Example 25

2-Bromo-4-(3-difluoromethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (Compound 25)

NaH (350 mg) was added to a solution of 3-difluoromethyl-6,6-dimethyl-1,5,6,7-tetrahydro-indazol-4-one (3.12 g) in DMSO (75 mL) at room temperature. After 20 minutes of stirring, 2-bromo-4-fluorobenzonitrile (4.67 g) was added and stirred at 45° C. overnight. The reaction was diluted with saturated aqueous NH₄Cl (100 mL), H₂O (100 mL). The mixture was extracted with ethyl acetate (4×150 mL), dried over Na₂SO₄, filtered, concentrated, purified by column chromatography eluting with a 1:2 mixture of ethyl acetate/hexanes. The concentrate of desired fractions was made into a slurry in ether, stirred for 2 h, filtered, washed by hexane to give pure solid 2-bromo-4-(6,6-dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (2.82 g, 49.2%). LCMS m/z: (M+H)=395.65, (MW: 394).

Example 26

4-(6,6-Dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide (Compound 26)

The following reaction was conducted at the 300 mg scale and in duplicate at the 500 mg scale: 4-Aminotetrahydropyran (154 mg, 1.52 mmol, 2.0 eq.) and sodium tert-butoxide (146 mg, 1.52 mmol, 2.0 eq.) were added to a stirred solution/suspension of 2-bromo-4-(6,6-dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (300 mg, 0.76 mmol, 1.0 eq.), palladium (II) acetate (8.5 mg, 0.04 mmol, 0.05 eq.), and 1,1′-bis(diphenylphosphino)ferrocene (42 mg, 0.08 mmol, 0.1 eq.) in toluene (2.25 mL). The reaction vial was capped, and the reaction mixture was heated for 20 min at 120° C. under microwave irradiation. The reaction mixture was diluted with water and ethyl acetate and combined. The layers were separated, and the aqueous layer was extracted with ethyl acetate (3×). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified on a Biotage system (SiO₂, hexanes-ethyl acetate) to afford 4-(6,6-dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzonitrile (897 mg, 65% yield) as a tan solid: LC/MS (m/z): [M+H]⁺ 415.2. Further elution with ethyl acetate afforded the title compound, 4-(6,6-dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, (131 mg, 9%) as a yellow solid: LC/MS (m/z): [M+H]⁺ 433.3.

To a solution/suspension of 4-(6,6-dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzonitrile (897 mg, 2.16 mmol, 1.0 eq) in 10.8 mL of 4:1 mixture of ethanol-dimethyl sulfoxide was added 1 mL of 1 M aqueous sodium hydroxide and 1 mL of 30% hydrogen peroxide. After 30 minutes the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound, 4-(6,6-dimethyl-4-oxo-3-difluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, (869 mg, 93%) as a tan solid: LC/MS (m/z): [M+H]⁺ 433.3.

Example 27

2-[3-(2-Dimethylamino-ethoxy)-4-methoxy-phenylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 27)

2-Bromo-4-(6,6-dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (100 mg, 0.28 mmol), Pd(OAc)₂ (3.1 mg, 5 mol %), DPPF (15.5 mg, 10 mol %) and NaOtBu (52 mg, 0.56 mmol) were added to a microwave vial. Toluene (0.5 mL) and 3-(2-dimethylamino-ethoxy)-4-methoxy-phenylamine (118 mg, 2 mol eq) were added and the vial was evacuated and back-filled with N₂. The reaction mixture was heated at 130° C. for 30 min (microwave). The reaction mixture was filtered and the solids washed with CH₂Cl₂. The product nitrile was purified using flash chromatography eluting with CH₂Cl₂ and methanol. This nitrile (32 mg, 0.66 mmol) was dissolved in ethanol (0.8 mL) and DMSO (0.2 mL) to which NaOH (5 N, 26 μL, 2 eq) and H₂O₂ (excess, 30% solution in H₂O) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was washed with H₂O and extracted with EtOAc. The product was purified using flash chromatography eluting with CH₂Cl₂ and methanol. The title compound was obtained as a yellow solid (10 mg, 30%); LC/MS (m/z): M+H=506.5.

Example 28

4-(3-Cyclopropylmethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 28)

5,5-Dimethyl-1,3-cyclohexanedione (1.051 g, 7.5 mmol, 1.5 eq), cyclopropylacetic acid (500.6 mg, 5.0 mmol), and 4-dimethylaminopyridine (916.3 mg, 7.5 mmol, 1.5 eq) were dissolved in 10 mL of CH₂Cl₂, cooled to 0° C. in an ice bath. A solution of N,N′-dicyclohexylcarbodiimide (1.238 g, 16.0 mmol, 1.2 eq) in 5 mL of CH₂Cl₂ was added dropwise over two minutes to the cyclohexanedione solution. The reaction mixture was then stirred at 0° C. for 10 minutes and at room temperature for 16 hours. The reaction mixture was then filtered and the filtrate purified by column chromatography (hexane to 30% EtOAc/hexane) to yield 1.022 g (92% yield) 2-(2-Cyclopropyl-acetyl)-5,5-dimethyl-cyclohexane-1,3-dione as a pale yellow oil.

2-(2-Cyclopropyl-acetyl)-5,5-dimethyl-cyclohexane-1,3-dione (111.1 mg, 0.5 mmol) and 4-cyanophenylhydrazine hydrochloride (84.8 mg, 0.5 mmol, 1.0 eq) were suspended in 4 mL of 3:1 EtOH:AcOH and microwaved at 100° C. for 10 minutes. The solvent was removed in vacuo and the resultant residue purified by column chromatography to yield 81.8 mg (51% yield) of 4-(3-Cyclopropylmethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile as an off-white powder.

After dissolving the nitrile in 10 mL of 4:1 EtOH-DMSO, approximately 0.1 mL of 1 N NaOH (aq.) and 0.1 mL of 30% H₂O₂ (aq.) were added and the solution stirred for 1.5 hours. The reaction mixture was poured into brine, extracted with EtOAc (×3), and the combined organics washed with brine (×2). The organic extracts were dried over Na₂SO₄ and concentrated in vacuo to afford 73.2 mg (43% yield) of 4-(3-Cyclopropylmethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide as an off-white solid. LCMS (m/z): M+H=339.4.

Example 29

2-[2-(2-Dimethylamino-ethoxy)-pyridin-4-ylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide, methansulfonic acid salt (Compound 29)

2-Chloro-4-nitropyridine (5.3 g, 33.43 mmol) and N,N-dimethylethanolamine (8 mL) were sealed in a pressure tube and stirred at 110° C. for 24 hours. The reaction mixture was then concentrated and dried under reduced pressure to remove excess N,N-dimethylethanolamine. The resulting yellow residue diluted with 1 N HCl, and a yellow solid, which was identified as 2-chloro-4-nitropyridine, was collected by filtration. The acidic aqueous solution was washed with EtOAc (×2), made basic by the addition of 3 N NaOH, and extracted into EtOAc (×4). The combined organics were dried over Na₂SO₄ and the solvent removed in vacuo, yielding 3.55 g (50.3% yield) of N,N-dimethyl-N′-(4-nitro-pyridin-2-yl)-ethane-1,2-diamine as an orange solid.

This product (3.55 g, 16.807 mmol) was dissolved in 60 mL ethanol. About five drops of conc. HCl was added, followed by addition of a spatula tip of Pd/C (10% wt). The reaction vessel was purged with N₂ filled with H₂ and evacuated three times, and filled with H₂ to a pressure of 60 psi. After shaking at room temperature for three hours, complete reduction of the nitro group was verified by LC/MS. The reaction mixture was filtered through Celite and the solvent removed in vacuo. The residue was then dissolved in EtOAc, washed with saturated aqueous NaHCO₃, water, and brine, and dried over Na₂SO₄. After removing the solvent in vacuo, 2.95 g (48.7% yield over two steps) of 2-(2-dimethylamino-ethoxy)-pyridin-4-ylamine as a waxy red solid was obtained.

2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (358.2 mg, 1.0 mmol), 2-(2-dimethylamino-ethoxy)-pyridin-4-ylamine (362.5 mg, 2.0 mmol, 2.0 eq.), palladium (II) acetate (11.2 mg, 5 mol %), 1,1′-bis(diphenylphosphino)ferrocene (55.4 mg, 10 mol %), and sodium tert-butixide (192.2 mg, 2.0 mmol, 2.0 eq.) were suspended in 4 mL of toluene. The reaction mixture was microwaved at 120° C. for 20 minutes. After cooling the reaction mixture, the solvent was removed in vacuo, and the residue diluted with water. The aqueous suspension was extracted with EtOAc×3 and the combined organics washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The intermediate nitrile and the desired amide were collected and combined after purifying by column chromatography (EtOAc/MeOH), and were dissolved in 20 mL of 4:1 EtOH/DMSO. Five drops of 1 N NaOH and five drops of 30% H₂O₂ were added, and the reaction mixture stirred at room temperature for 2 hours. The solution was diluted with water, extracted into EtOAc (×3), and the combined organics washed with brine (×2), dried over Na₂SO₄, and concentrated under reduced pressure. The resultant residue was purified by column chromatography (EtOAc/MeOH), yielding 347.3 mg (72.9% yield) of a pink foam. This was dissolved in CH₂Cl₂ and treated with of one equivalent of methanesulfonic acid, stirring at room temperature for 1 hour. The mixture was evaporated under reduced pressure to yield the title compound. LCMS m/z (M+H)=477.3.

Example 30

2-(2,3-Dihydroxy-propylamino)-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 30)

A mixture of 2,4-Difluoro-benzonitrile (1.39 g, 10 mmol), 3-amino-propane-1,2-diol (0.911 g, 10 mmol), and ethyl-diisopropyl-amine (1.74 mL) in DMSO (10 mL) was microwaved at 200° C. for 7 min. Then the reaction mixture was poured into a saturated NH₄Cl aq. solution (100 mL), extracted with EtOAc (3×100 mL), dried over Na₂SO₄, filtered, concentrated. The crude mixture was purified by flash silica gel chromatography (EtOAc-Hexane 1:1) to give 2-(2,3-Dihydroxy-propylamino)-4-fluoro-benzonitrile (0.87 g, 41.4% yield). LCMS (m/z): M+H=211.

To a mixture of 6,6-Dimethyl-3-trifluoromethyl-1,5,6,7-tetrahydro-indazol-4-one (0.961 g, 4.14 mmol, 1 eq) and NaH (99 mg, 4.14 mmol, 1 eq) in dimethyl acetamide (20 mL) was added slowly 2-(2,3-Dihydroxy-propylamino)-4-fluoro-benzonitrile (0.87 g, 4.14 mmol, 1 eq). Then the reaction mixture was stirred at 150° C. overnight, cooled, poured into saturated NH₄Cl aq. solution (100 mL), extracted by EtOAc (3×150 mL), dried over Na₂SO₄, filtered, concentrated. The crude product was purified by flash silica gel chromatography, eluted by EtOAc to give 2-(2,3-Dihydroxy-propylamino)-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (1.7 g, 97% yield). LCMS (m/z): M+H=423.

2-(2,3-Dihydroxy-propylamino)-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (1.7 g, 4 mmol, 1 eq), NaOH (806 mg, 20 mmol, 5 eq), and H₂O₂ (3 mL) were dissolved in EtOH-water (4:1) (40 mL). The mixture was microwaved at 120° C. for 15 min, then concentrated to dryness, and purified by flash chromatography, eluted by 10% MeOH in EtOAc to give pure 2-(2,3-Dihydroxy-propylamino)-4-(6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (0.52 g, 29% yield). LCMS (m/z): M+H=441.

Example 31

4-(6,6-Dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-thiopyran-4-ylamino)-benzamide (Compound 31)

1-(2-Bromo-4-cyanophen-4-yl)-3-trifluoromethyl-6,6-dimethyltetrahydroindazal-4-one (313 mg, 0.76 mmol), Pd(OAc)₂ (8.7 mg, 5 mol %), DPPF (44.5 mg, 10 mol %) and NaOtBu (153 mg, 1.52 mmol) were added to a microwave vial. Toluene (1 mL) and 4-aminotetrahydrothiopyran (116 mg, 1.3 mol eq) were added and the vial was evacuated and back-filled with N₂. The reaction mixture was heated at 130° C. for 20 min (microwave). The reaction mixture was filtered and the solids washed with CH₂Cl₂. The product was purified using flash chromatography eluting with hexanes and EtOAc. Product was recovered as a off-white solid (23 mg, 7%), LCMS (M+H)⁺=449.4

This pyrazole (23 mg, 0.05 mmol) was dissolved in ethanol (0.8 mL) and DMSO (0.2 mL) to which NaOH (5 N, 21 μL, 2 mol eq) was added and the reaction mixture was heated at 70° C. for 12 hours. The reaction mixture was washed with water and EtOAc. The product was purified using flash chromatography eluting with hexanes and EtOAc. The title compound was obtained as an off-white solid (16 mg, 67%); LC/MS (m/z): M+H=467.2.

Example 32

4-(3-Difluoromethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-2-(tetrahydro-thiopyran-4-ylamino)-benzamide (Compound 32)

2-Bromo-4-(3-difluoromethyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (300 mg, 0.76 mmol), Pd(OAc)₂ (8.7 mg, 5 mol %), DPPF (44.5 mg, 10 mol %) and NaOtBu (153 mg, 1.52 mmol) were added to a microwave vial. Toluene (1 mL) and 4-aminotetrahydrothiopyran (116 mg, 1.3 mol eq) were added and the vial was evacuated and back-filled with N₂. The reaction mixture was heated at 120° C. for 15 min (microwave). The reaction mixture was filtered and the solids washed with CH₂Cl₂. The product was purified using flash chromatography eluting with hexanes and EtOAc. Product was recovered as an off-white solid (70 mg, 21%).

The preceding product pyrazole (70 mg, 0.16 mmol) was dissolved in ethanol (0.8 mL) and DMSO (0.2 mL) to which NaOH (5 N, 65 mL, 2 eq) was added and the reaction mixture was heated at 70° C. for 12 hours. The reaction mixture was washed with H₂O and EtOAc. The product was purified using flash chromatography eluting with hexanes and EtOAc. The title compound was obtained as an off-white solid (40 mg, 56% yield), LC/MS (m/z): M+H=449.2.

Example 33

2-[(Tetrahydro-furan-2-ylmethyl)-amino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 33)

2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (1.0 mmol, 358 mg), palladium acetate (0.13 mmol, 30 mg), 1,1′-bis(diphenylphosphino)ferrocene (0.1 mmol, 56 mg), sodium t-butoxide (2 mmol, 192 mg), toluene (2 mL), and 2-(aminomethyl)tetrahydrofuran (3 mmol, 0.31 mL) were combined in a microwave tube, stirred briefly, and heated in a Personal Chemistry microwave set at high absorbance to 110° C. for 900 seconds. After cooling, the reaction mixture was taken up in ethyl acetate (200 mL) and washed with water (50 mL). The organic phase was dried over magnesium sulfate, filtered, and concentrated. The residue was subjected to chromatography, affording the desired nitrile intermediate as a tan solid (305 mg, 81% yield).

DMSO (6 drops) and ethanol (4 mL) were added to the above nitrile (0.79 mmol, 300 mg). The flask was lowered into a 50° C. oil bath and KOH (5.8 mmol, 325 mg) was added, followed by 30% hydrogen peroxide (ca. 10 mmol, 1 mL). After 45 minutes, the reaction was taken up in ethyl acetate (100 mL) and washed with water (50 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. Chromatography of the residue afforded the title compound as a white solid (313 mg, 100% yield). LCMS (m/z): M+H=397.3.

Example 34

2-[3-(2-Oxo-pyrrolidin-1-yl)-propylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 34)

2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (1.0 mmol, 358 mg), palladium acetate (0.13 mmol, 30 mg), 1,1′bis(diphenylphosphino)ferrocene (0.1 mmol, 56 mg), sodium t-butoxide (2 mmol, 192 mg), toluene (2 mL), and N-(3-aminopropyl)-2-pyrrolidinone (2 mmol, 0.28 mL) were combined in a 2-5 mL microwave tube, stirred briefly, and heated in a Personal Chemistry microwave set at high absorbance to 110° C. for 900 seconds. After cooling, the reaction mixture was taken up in ethyl acetate (200 mL) and washed with water (25 mL). The aqueous layer was extracted with additional ethyl acetate (200 mL), and the combined organic phase was dried over magnesium sulfate, filtered, and concentrated. The residue was subjected to chromatography, affording the desired nitrile as a tan solid (258 mg, 61%).

DMSO (0.1 mL) and ethanol (4 mL) were added to the above nitrile (0.60 mmol, 250 mg). The flask was lowered into a 50° C. oil bath and KOH (4.5 mmol, 255 mg) was added, followed by 30% hydrogen peroxide (ca 10 mmol, 1 mL). After 30 minutes, the reaction was taken up in ethyl acetate (100 mL) and washed with water (50 mL). The aqueous layer was extracted with additional ethyl acetate (100 mL). The combined organic layer was dried over magnesium sulfate, filtered, and concentrated. Chromatography of the residue afforded the title benzamide as a white solid (187 mg, 71%). LCMS (m/z): M+H=438.2.

Example 35

2-(2,2,2-Trifluoro-ethylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide (Compound 35)

2-Bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (2.0 mmol, 714 mg), palladium acetate (0.13 mmol, 60 mg), 1,1′-bis(diphenylphosphino) ferrocene (0.2 mmol, 112 mg), sodium t-butoxide (4 mmol, 384 mg), toluene (4 mL), and 2,2,2-trifluoroethylamine (8 mmol, 0.63 mL) were combined in a 2-5 mL microwave tube, stirred briefly, and heated in a Personal Chemistry microwave set at high absorbance to 110° C. for 900 seconds. After cooling, the reaction mixture was taken up in ethyl acetate (200 mL) and washed with water (25 mL). The organic phase was dried over magnesium sulfate, filtered, and concentrated. The residue was subjected to chromatography, affording a mixture of the anticipated 2-(2,2,2-trifluoro-ethylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzonitrile (346 mg, 50%) as a tan solid, and the desired ultimate product, 2-(2,2,2-trifluoro-ethylamino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indazol-1-yl)-benzamide, as a tan solid (77 mg, 10%). LCMS (m/z): M+H=395.1.

Example 36

The following compounds are prepared essentially according to the procedures set forth in Schemes 1-4 above and described in the above examples.

Compound No. Structure Name 36

2-(allylamino)-4-(3-methyl-4-oxo- 4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 324 .1 37

2-(cyclopropylamino)-4-(3-methyl- 4-oxo-4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 324.1 38

2-(2-methoxyethylamino)-4-(3- methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 342.1 39

4-(3-methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 269.1 40

4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 297.1 41

4-(3-methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)-2- (phenylamino)benzamide; M + H = 360.1 42

2-(trans-4- hydroxycyclohexylamino)-4-(3- methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 382.2 43

4-(3-methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)-2-(3,4,5- trimethoxyphenylamino)benzamide; M + H = 450.2 44

2-(2-(dimethylamino)ethylamino)-4- (3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 383.2 45

2-(2-(dimethylamino)ethylamino)-4- (3-methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 355.2 46

2-(pyridin-4-ylmethylamino)-4- (3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 403.2 47

4-(3-methyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)-2-(pyridin- 3-ylmethylamino)benzamide; M + H = 375.1 48

tert-butyl 4-(2-carbamoyl-5- (3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydroindol-1- yl)phenylamino)piperidine-1- carboxylate; M + H = 495.2 49

2-amino-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 312.1 50

2-(allylamino)-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 352.2 51

2-(1-methylpiperidin-4-ylamino)-4- (3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 409.2 52

2-(piperidin-4-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7- tetrahydroindol-1-yl)benzamide; M + H = 395.2 53

3-butoxy-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 369.2 54

2-(2,3-dihydro-1H-inden-1- ylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 428.2 55

1-(2-carbamoyl-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydroindol-1- yl)phenyl)urea M + H = 355.1

Example 37

5,5-dimethyl-2-(2-oxopropyl)cyclohexane-1,3-dione (Compound 56)

An oven dried flask was charged with sodium hydride (3.61 g, 142.7 mmol) to which 200 mL of anhydrous DMF was added. The flask was cooled in an ice bath before adding 5,5-dimethyl-1,3-cyclohexanedione (20.0 g, 142.7 mmol) and chloroacetone (11.36 mL, 142.7 mmol) in 100 mL DMF in a controlled manner. The reaction was allowed to warm to RT and stirred for 3 h. Saturated NH₄Cl was added and the mixture was washed several times with EtOAc. The combined organic layer was dried over MgSO₄, filtered, the solvent removed in vacuo (below 40° C.). LCMS m/z M+H=197.1.

Example 38

2,6,6-trimethyl-6,7-dihydro-1H-indol-4(5H)-one (Compound 57)

The crude tri-ketone from Example 37 was dissolved in 300 mL of acetic acid to which ammonium acetate (55 g, 0.714 mmol) was added. The reaction mixture was heated at 65° C. until all starting material had disappeared (2-3 h), cooled to RT, added to H₂O, and washed with EtOAc. The organic layer was washed with saturated NaHCO₃ (×3), brine (×1) and dried over MgSO₄. Solvent was removed in vacuo and the oily residue was passed through a plug of silica. The appropriate fractions were collected and solvent was removed. The resulting solid was washed with EtOAc and hexanes (if too much hexanes is added the material crashing back out of solution after the addition of EtOAc will be gummy. To remedy this simply add a little EtOAc). The solid was filtered and washed with hexanes. More solid can be recovered by removing the solvent and repeating this procedure. LCMS m/z M+H=178.1. Approximately 5 g of a tan solid was collected and identified as 2,6,6-trimethyltetrahydroindol-4-one.

Example 39

2-bromo-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzonitrile (Compound 58)

Pyrrole (2,6,6-trimethyltetrahydroindol-4-one) (1.5 g, 8.5 mmol) and 2-bromo-4-fluorobenzonitrile (1.69 g, 8.5 mmol) were dissolved in anhydrous DMF (50 mL). To this NaH (95%, 408 mg, 17.0 mmol) was added and stirred at 50° C. for 1 h. The reaction mixture was cooled to RT and H₂O was added. Product crashed out of solution and was filtered and dried under vacuo (2.4 g, 79%). (100% clean by LCMS, product M+H=357).

Example 40

3-fluoro-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzonitrile (Compound 59)

Pyrrole (2,6,6-trimethyltetrahydroindol-4-one) (1.0 g, 5.6 mmol) and 3,4-difluorobenzonitrile (785 mg, 5.6 mmol) were dissolved in anhydrous DMF (20 mL). To this NaH (95%, 270 mg, 11.2 mmol) was added and stirred at 50° C. for 30 min. The reaction mixture was cooled to RT and washed with H₂O and EtOAc. The organic layer was dried over MgSO₄. Column chromatography on silica eluting with EtOAc-hexanes (1:1) gave the product as a yellow solid (100% clean by LCMS, product M+H=397.1).

Example 41

3-butoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide (Compound 60)

3-Fluoro-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile (148 mg, 0.5 mmol) and 1-butanol (185.3 mg, 2.5 mmol) were dissolved in anhydrous DMF (1.5 mL). To this solution was added NaH (24.0 mg, 1 mmol). After purging the reaction vessel (Personal Chemistry Microwave Vial) with nitrogen, the reaction vessel was sealed and heated to 100° C. for 300 seconds in an Emyrs Optimizer Microwave. After cooling, the reaction mixture was diluted with H₂O and extracted into EtOAc (×2). The combined organics were washed with brine (×2), dried over Na₂SO₄, and concentrated to dryness. The yellow residue (3-Butoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile) was then dissolved in EtOH (3 mL) and treated with 1 mL of 1 N NaOH (aq) and a catalytic amount of H₂O₂. Quantitative conversion of the nitrile to the amide occurred after heating this solution at 65° C. for 3 hours. Column chromatography on silica eluting with EtOAc gave the product as a white solid (119.9 mg, 65%). (100% clean by LC/MS, product M+H=369.2).

Example 42

2-(phenylamino)-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide (Compound 61)

2-Bromo-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile (107.2 mg, 0.3 mmol), aniline (111.8 mg, 1.2 mmol), Pd(OAc)₂ (10.1 mmol, 5 mol %), DPPF (16.6 mg, 10 mol %), and NaOtBu (57.7 mg, 0.6 mmol) were placed in a Personal Chemistry Microwave Vial. The reagents were suspended in 2.5 mL of anhydrous toluene and the vessel purged with nitrogen. The reaction vessel was sealed and heated to 110° C. for 480 seconds. Upon cooling, the reaction mixture was filtered through SiO₂ (eluted with 2:1 EtOAc/hexanes) and the eluent concentrated in vacuo. The residue was then dissolved in 2 mL EtOH and treated with 0.6 mL of 1 N NaOH and a catalytic amount of H₂O₂. After stirring this solution at 50° C. for 2 hours, the mixture of nitrile and amide was purified by column chromatography (silica, EtOAc/hexanes). The product 2-(phenylamino)-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydroindol-1-yl)benzamide was isolated as a yellow powder (55.6 mg, 47%). (100% clean by LC/MS, product M+H=388.1). The corresponding nitrile was also isolated (46.9 mg, 42%). (100% clean by LC/MS).

Example 43

(Z)-3-butoxy-N′-hydroxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzimidamide (Compound 62)

Treatment of 3-Butoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-indol-1-yl)-benzonitrile with hydroxylamine hydrochloride affords the title compound, LCMS m/z M+H=384.2.

Example 44

The following compounds are prepared essentially according to the procedures forth in Scheme 7-9 and described in the preceding examples.

Compound No. Structure Name 63

2-Benzylamino-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-indol-1-yl)- benzamide; M + H = 402.2 64

3-Prop-2-ynyloxy-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-indol-1-yl)- benzamide; M + H = 351.1 65

2-Ethynyl-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-indol-1-yl)- benzamide; M + H = 321.1 66

2-(4-Methoxy-phenylamino)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro- indol-1-yl)-benzamide; M + H = 418.2 67

2-Cyclohexylamino-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-indol-1-yl)- benzamide; M + H = 394.1 68

2-(butylamino)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydroindol-1- yl)benzamide; M + H = 368.2 69

4-Methyl-3-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-indol-1-yl)- benzamide M + H = 311.1

Example 45

The following compounds are prepared essentially according to the procedures forth in Scheme 1-9 and described in the preceding examples.

Compound No. M + H Name 70 379.1 3-(3-thienyl)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide 71 311.1 2-methyl-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide 72 412.1 2-[(3-ethynylphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 73 422.1 2-[(4-chlorophenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 74 360.1 2-anilino-4-(2-methyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide 75 389.1 3-anilino-5-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)pyridine-2- carboxamide 76 478.2 2-[(3,4,5-trimethoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 77 374.1 2-pyridin-4-yl-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide 78 412.2 N-[2-(aminocarbonyl)-5-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]-L-valine 79 382.2 2-morpholin-4-yl-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide 80 363.1 2-(1H-imidazol-1-yl)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 81 513.2 4-(3-chloro-2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)-2-[(3,4,5- trimethoxyphenyl)amino]benzamide 82 404.1 2-[(4-hydroxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 83 406.2 2-[(1-ethyl-1H-pyrazol-5-yl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 84 393.1 2-[(5-methylisoxazol-3-yl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 85 403.1 2-{[4-(aminocarbonyl)phenyl]amino}-4-(2- methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 86 436.1 4-(4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)- 2-[(3,4,5-trimethoxyphenyl)amino]benzamide 87 419.2 2-[(6-methoxypyridin-3-yl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 88 310.1 2-(allylamino)-4-(4-oxo-4,5,6,7-tetrahydro- 1H-indol-1-yl)benzamide 89 283.1 4-(2,3-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide 90 361 3-bromo-4-(2,3-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide 91 338.1 2-(allylamino)-4-(2,3-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide 92 356.1 4-(2,3-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)-2-[(2- methoxyethyl)amino]benzamide 93 519.2 2-({3-[3-(dimethylamino)propoxy]-4- methoxyphenyl}amino)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 94 397.2 2-(morpholin-4-ylamino)-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 95 371.2 2-[(2-methoxyethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 96 425.2 2-[(2-morpholin-4-ylethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 97 389.1 2-(pyridin-4-ylamino)-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 98 354.1 2-(acetylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide 99 395.2 2-(4-methylpiperazin-1-yl)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 100 367.2 2-[(cyclopropylmethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 101 384.1 2-[(methoxyacetyl)amino]-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 102 326.1 2-ethyl-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide 103 386.1 2-(butylthio)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide 104 505.2 2-({3-[2-(dimethylamino)ethoxy]-4- methoxyphenyl}amino)-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 105 406.1 2-(pyridin-4-ylthio)-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide 106 417.2 2-{[(1R)-1-phenylethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 107 533.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- [(3,4,5-trimethoxyphenyl)amino]benzamide 108 476.2 2-({2-[2-(dimethylamino)ethoxy]pyridin-4- yl}amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide 109 480.2 2-{[1-(N,N-dimethylglycyl)piperidin-4- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide 110 359.1 4-(6,6-dimethyl-4-oxo-3-phenyl-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide 111 455.2 2-[(2-{[2-(aminocarbonyl)-5-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)phenyl]amino}ethyl)amino]-2-oxoethyl acetate 112 413.2 2-{[2-(glycoloylamino)ethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide 113 419.1 2-{[2-(methylsulfonyl)ethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 114 419.2 2-[(4-methoxyphenyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 115 406.1 2-[(6-oxo-1,6-dihydropyridin-3-yl)amino]-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro- 1H-indazol-1-yl)benzamide 116 415.2 2-(cyclopent-3-en-1-ylamino)-4-[3- (difluoromethyl)-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide 117 367.2 2-(cyclobutylamino)-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide 118 455.2 2-[trans-4-(2-Hydroxy-ethoxy)- cyclohexylamino]-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-indazol-1-yl)-benzamide 119 411.2 2-(trans-4-Hydroxy-cyclohexylamino)-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro- indazol-1-yl)-benzamide 120 415.2 2-(2-Methoxy-1-methoxymethyl-ethylamino)-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro- indazol-1-yl)-benzamide; 121 415.2 2-{[3-hydroxy-1-(2- hydroxyethyl)propyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 122 469.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-{[2- methoxy-1- (methoxymethyl)ethyl]amino}benzamide 123 451.1 2-{[3-(methylsulfinyl)phenyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro- 1H-indazol-1-yl)benzamide 124 528.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-{[1- (methylsulfonyl)piperidin-4- yl]amino}benzamide 125 465.2 4-(6,6-Dimethyl-4-oxo-3-trifluoromethyl- 4,5,6,7-tetrahydro-indazol-1-yl)-2-(trans-4- hydroxy-cyclohexylamino)-benzamide 126 509.2 4-(6,6-Dimethyl-4-oxo-3-trifluoromethyl- 4,5,6,7-tetrahydro-indazol-1-yl)-2-[trans-4- (2-hydroxy-ethoxy)-cyclohexylamino]- benzamide 127 537.3 2-{[1-(3-morpholin-4-ylpropanoyl)piperidin- 4-yl]amino}-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide 128 508.2 2-[trans-4-(2-Amino-ethoxy)- cyclohexylamino]-4-(6,6-dimethyl-4-oxo-3- trifluoromethyl-4,5,6,7-tetrahydro-indazol- 1-yl)-benzamide 129 453.2 2-[(1-glycylpiperidin-4-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide 130 454.2 2-[trans-4-(2-Amino-ethoxy)- cyclohexylamino]-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-indazol-1-yl)-benzamide 131 446.1 2-{[1-(methylsulfonyl)azetidin-3-yl]amino}- 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro- 1H-indazol-1-yl)benzamide 132 433.1 2-{[3-(methylsulfonyl)propyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro- 1H-indazol-1-yl)benzamide 133 488.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-({2- [(methylsulfonyl)amino]ethyl}amino)benzamide 134 338.1 4-(3-but-3-en-1-yl-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide 135 460.1 2-{[(3S)-1-(methylsulfonyl)pyrrolidin-3- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide 136 502.1 2-({2-[(dimethylamino)sulfonyl]ethyl}amino)- 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide 137 327.1 4-[3-(2-Amino-ethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-indazol-1-yl]-benzamide

Example 46

The following compounds have been prepared essentially according to the procedures set forth in Schemes 1-9 above and described in the above examples.

Com- pound M + No. H Name 138 285.1 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzoic acid; 139 284.1 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 140 297.1 4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 141 313.1 4-[(4Z)-4-(methoxyimino)-6,6-dimethyl-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 142 299.1 4-[(4Z)-4-(hydroxyimino)-6,6-dimethyl-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 143 311.1 4-methyl-3-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 144 297.1 3-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 145 332.1 2-chloro-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzoic acid; 146 327.1 4-[(4Z)-4-(ethoxyimino)-6,6-dimethyl-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 147 375.1 4-[(4Z)-6,6-dimethyl-4-(phenoxyimino)-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 148 355.2 4-[(4Z)-4-(isobutoxyimino)-6,6-dimethyl- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide; 149 339.1 4-{(4Z)-4-[(allyloxy)imino]-6,6-dimethyl- 4,5,6,7-tetrahydro-1H-indazol-1-yl}benzamide; 150 383.2 4-{(4Z)-6,6-dimethyl-4-[(tetrahydro-2H-pyran-2- yloxy)imino]-4,5,6,7-tetrahydro-1H-indazol-1- yl}benzamide; 151 389.1 4-{(4Z)-4-[(benzyloxy)imino]-6,6-dimethyl- 4,5,6,7-tetrahydro-1H-indazol-1-yl}benzamide; 152 312.1 4-[(4E)-4-(hydroxyimino)-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl]benzamide; 153 326.1 4-[(4E)-4-(methoxyimino)-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl]benzamide; 154 352.1 4-{(4E)-4-[(allyloxy)imino]-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl}benzamide; 155 368.2 4-[(4E)-4-(isobutoxyimino)-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl]benzamide; 156 402.2 4-{(4E)-4-[(benzyloxy)imino]-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl}benzamide; 157 340.1 3-[(4Z)-4-(methoxyimino)-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl]-4- methylbenzamide; 158 326.1 3-[(4Z)-4-(hydroxyimino)-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl]-4- methylbenzamide; 159 377.1 4-[6-(1,3-benzodioxol-5-yl)-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzoic acid; 160 376.1 4-[6-(1,3-benzodioxol-5-yl)-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 176 383.2 2-{[2-(dimethylamino)ethyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 177 388.1 2-anilino-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 178 315.1 3-fluoro-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 179 359.1 4-(6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 180 331.1 2-chloro-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 181 402.2 2-(benzylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 182 375 2-bromo-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 183 357.1 3-(2-hydroxyethoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 184 312.1 2-amino-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 185 385.1 3-(tert-butylthio)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 186 405.1 3-(phenylthio)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 187 385.1 3-(butylthio)-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 188 340.1 2-(dimethylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 189 327.1 3-methoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 190 341.1 3-ethoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 191 355.1 3-propoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 192 403.1 3-(benzyloxy)-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 193 426.2 3-(2-morpholin-4-ylethoxy)-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 194 404.1 3-(pyridin-2-ylmethoxy)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 195 404.1 3-(pyridin-4-ylmethoxy)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 196 399.2 3-(2-isopropoxyethoxy)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 197 410.2 3-(2-pyrrolidin-2-ylethoxy)-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 198 411.2 3-(tetrahydro-2H-pyran-2-ylmethoxy)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 199 397.2 3-(tetrahydro-2H-pyran-4-yloxy)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 200 368.2 3-(butylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 201 331.1 3-chloro-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 202 393.1 3-(1H-imidazol-4-ylmethoxy)-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 203 418.2 2-[(4-methoxyphenyl)amino]-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 204 370.1 3-butoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzoic acid; 205 388.1 3-anilino-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 206 402.2 3-(benzylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 207 371.1 3-(3-hydroxypropoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 208 385.2 3-(3-hydroxybutoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 209 387.1 3-(2,3-dihydroxypropoxy)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 210 340.1 N-butyl-4-(6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 211 383.2 3-(2-methylbutoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 212 383.2 3-(pentyloxy)-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 213 383.2 3-(3-methylbutoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 214 313.1 3-hydroxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 215 360.1 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)-N-phenylbenzamide; 216 394.2 2-(cyclohexylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 217 395.2 3-(cyclohexyloxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 218 381.2 3-(pent-4-en-1-yloxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 219 432.1 2-(1,3-benzodioxol-5-ylamino)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 220 396.2 2-(hexylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 221 341.1 3-butoxy-4-(2-methyl-4-oxo-4,5,6,7-tetrahydro- 1H-indol-1-yl)benzamide; 222 385.2 3-(4-hydroxybutoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 223 397.2 3-[(3-methyloxetan-3-yl)methoxy]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 224 384.2 3-(4-aminobutoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 225 383.1 3-(tetrahydrofuran-3-yloxy)-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 226 397.2 3-(tetrahydrofuran-2-ylmethoxy)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 227 381.2 3-[(1-ethylprop-2-en-1-yl)oxy]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 228 362 2-bromo-4-(6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 229 409.1 3-(2-thienylmethoxy)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 230 283.1 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 231 390.1 2-[(methylsulfonyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 232 354.1 2-(acetylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 233 355.1 2-[(aminocarbonyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 234 416.1 2-(benzoylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 235 382.2 2-(butyrylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 236 342.1 3-ethoxy-5-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)pyridine-2- carboxamide; 237 389.1 2-(pyridin-3-ylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 238 390.1 2-(pyridin-2-ylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzoic acid; 239 432.2 2-[(3-ethoxyphenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 240 418.2 2-[(3-methoxyphenyl)amino]-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 241 356.1 3-butoxy-4-(6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 242 371.2 3-butoxy-4-(6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)-N′- hydroxybenzenecarboximidamide; 243 326.1 N′-hydroxy-3-methyl-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1- yl)benzenecarboximidamide; 244 311.1 3-methyl-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 245 346.1 2-chloro-N-hydroxy-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1- yl)benzenecarboximidamide; 246 348.1 2,3-difluoro-N-hydroxy-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzenecarboximidamide; 247 355.1 8-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)-2,3-dihydro-1,4-benzodioxine-5- carboxamide; 248 367.2 2-pentyl-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 249 367.2 3-pentyl-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 250 460.2 2-[(4-butoxyphenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 251 403.2 2-anilino-N′-hydroxy-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1- yl)benzenecarboximidamide; 252 472.1 2-{[4-(trifluoromethoxy)phenyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 253 440.1 2-[(2-chloro-4-fluorophenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 254 436.1 2-[(2-chloro-4-methylphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 255 452.1 2-[(2-chloro-4-methoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 256 448.2 2-[(3,4-dimethoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 257 436.2 2-[(3-fluoro-4-methoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 258 448.2 2-[(3,5-dimethoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 259 448.2 2-[(2,5-dimethoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 260 432.2 2-[(4-ethoxyphenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 261 406.1 2-[(4-fluorophenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 262 389.1 2-phenoxy-4-(2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 263 405.1 2-(phenylthio)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 264 352.1 2-(cyclopropylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 265 350.1 2-(prop-2-yn-1-ylamino)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 266 371.1 3-(propylthio)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 267 386.1 N-hydroxy-3-(propylthio)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzenecarboximidamide; 268 460.2 N-[2-(aminocarbonyl)-5-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)phenyl]-L- phenylalanine; 269 371.2 3-butoxy-4-[(4Z)-4-(hydroxyimino)-6,6-dimethyl- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide; 270 469.3 2-(diethylamino)ethyl 3-butoxy-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzoate; 271 546.1 2-[(2-chloro-3,4,5-trimethoxyphenyl)amino]-4- (3-chloro-2,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 272 464.2 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)-2-[(3,4,5- trimethoxyphenyl)amino]benzamide; 273 450.2 4-(2-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)-2-[(3,4,5- trimethoxyphenyl)amino]benzamide; 274 442.1 2-[(3,4,5-trifluorophenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 275 410.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 276 408.2 2-[(4-oxocyclohexyl)amino]-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 277 402.2 2-[(4-methylphenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 278 428.2 2-(2,3-dihydro-1H-inden-4-ylamino)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 279 430.2 2-[(2-propylphenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 280 430.2 2-[(2-isopropylphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 281 351.1 2-(3-hydroxyprop-1-yn-1-yl)-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 282 512.1 2-[(2-chloro-3,4,5-trimethoxyphenyl)amino]-4- (2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 283 331.1 4-(4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide; 284 442.1 2-[(2,4,5-trifluorophenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 285 492.2 2-[(3,4,5-trimethoxybenzyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 286 406.1 2-[(2-fluorophenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 287 406.2 2-[(3-fluorophenyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 288 420.2 2-[(4-fluoro-3-methylphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 289 434.2 2-[(3-hydroxy-4-methoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 290 436.2 2-[(2-fluoro-4-methoxyphenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 291 396.2 2-(tetrahydro-2H-pyran-4-ylamino)-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 292 424.1 2-[(2,4-difluorophenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 293 424.1 2-[(3,4-difluorophenyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 294 445.2 2-anilino-4-{5-[(dimethylamino)methyl]-2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl}benzamide; 295 346.1 4-[(4E)-4-(hydroxyimino)-2-phenyl-4,5,6,7- tetrahydro-1H-indol-1-yl]benzamide; 296 494.2 2-{[4-(benzyloxy)phenyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 297 396.2 2-[(tetrahydrofuran-2-ylmethyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 298 398.2 2-[(1,3-dioxolan-2-ylmethyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 299 384.2 2-[(2-methoxy-1-methylethyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 300 400.2 2-{[2-(2-hydroxyethoxy)ethyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 301 356.1 2-[(4-hydroxybutyl)amino]-4-(2-methyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 302 411.2 4-(2-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)-2-[(3-morpholin-4- ylpropyl)amino]benzamide; 303 403.2 2-[(pyridin-2-ylmethyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 304 503.2 2-{[2-(diethylamino)-4-ethoxyphenyl]amino}-4- (2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 305 454.1 2-{[4-(difluoromethoxy)phenyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 306 462.2 2-[(3,4-dimethoxybenzyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 307 370.2 2-[(3-hydroxypropyl)amino]-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 308 352.1 2-(allylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 309 493.2 4-[(4E)-4-(hydroxyimino)-2,6,6-trimethyl- 4,5,6,7-tetrahydro-1H-indol-1-yl]-2-[(3,4,5- trimethoxyphenyl)amino]benzamide; 310 384.2 2-[(3-methoxypropyl)amino]-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 311 389.1 2-(pyridin-4-ylamino)-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 312 420.2 2-{[3-(1H-imidazol-1-yl)propyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 313 406.2 2-{[2-(1H-imidazol-1-yl)ethyl]amino}-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 314 379.1 2-(isoxazol-3-ylamino)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 315 403.2 2-[(pyridin-3-ylmethyl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 316 340.1 4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)phthalamide; 317 348 3-bromo-N′-hydroxy-4-(4-oxo-4,5,6,7-tetrahydro- 1H-indol-1-yl)benzenecarboximidamide; 318 342.1 4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)phthalic acid; 319 467.3 2-[(10-aminodecyl)amino]-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 320 324.1 2-(allylamino)-4-(2-methyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 321 386.1 2-(2,3-dihydro-1H-inden-1-ylamino)-4-(4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 322 338.1 2-(cyclopropylamino)-4-(2,3-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 323 342.1 2-[(2-methoxyethyl)amino]-4-(2-methyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 324 324.1 3-[(cyclopropylmethyl)amino]-4-(4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 325 492.2 2-{[3-(3-hydroxypropoxy)-4- methoxyphenyl]amino}-4-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 326 324.1 2-(allylamino)-4-(3-methyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 327 324.1 2-(cyclopropylamino)-4-(3-methyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 328 342.1 2-[(2-methoxyethyl)amino]-4-(3-methyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 329 269.1 4-(2-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide; 330 297.1 4-(3-ethyl-2-methyl-4-oxo-4,5,6,7-tetrahydro- 1H-indol-1-yl)benzamide; 331 269.1 4-(3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)benzamide; 332 487.2 2-[(2-{2-[2-(2- aminoethoxy)ethoxy]ethoxy}ethyl)amino]-4- (2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 333 382.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(2- methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 334 297.1 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 335 360.1 2-anilino-4-(3-methyl-4-oxo-4,5,6,7-tetrahydro- 1H-indol-1-yl)benzamide; 336 382.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(3- methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 337 396.2 4-(2,3-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)-2-[(trans-4- hydroxycyclohexyl)amino]benzamide; 338 374.1 2-anilino-4-(2,3-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 339 450.2 4-(3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indol- 1-yl)-2-[(3,4,5- trimethoxyphenyl)amino]benzamide; 340 383.2 2-{[2-(dimethylamino)ethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 341 355.2 2-{[2-(dimethylamino)ethyl]amino}-4-(3-methyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 342 395.2 2-(piperidin-4-ylamino)-4-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 343 298.1 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 344 333 2-bromo-5-(4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 345 410.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 346 409.2 2-[(1-methylpiperidin-4-yl)amino]-4-(2,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 347 453.2 (4-{[2-(aminocarbonyl)-5-(2,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}piperidin-1-yl)acetic acid; 348 370.2 2-[(2-methoxyethyl)amino]-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 349 403.2 2-[(pyridin-4-ylmethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 350 396.2 2-(tetrahydro-2H-pyran-4-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 351 478.2 2-[(3,4,5-trimethoxyphenyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 352 340.1 4-(3-isobutyl-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 353 312.1 2-amino-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 354 352.1 2-(allylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 355 409.2 2-[(1-methylpiperidin-4-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 356 395.2 2-(piperidin-4-ylamino)-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 357 369.2 3-butoxy-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 358 428.2 2-(2,3-dihydro-1H-inden-1-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 359 408.2 2-[(4-oxocyclohexyl)amino]-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 360 355.1 2-[(aminocarbonyl)amino]-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 361 397.2 2-(tetrahydro-2H-pyran-4-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 362 376 2-bromo-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 363 440.2 2-[(3-morpholin-4-ylpropyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 364 397.2 2-[(tetrahydrofuran-2-ylmethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 365 523.3 2-{[trans-4-(2-morpholin-4- ylethoxy)cyclohexyl]amino}-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 366 435.2 2-[(8-methyl-8-azabicyclo[3.2.1]oct-3- yl)amino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indol-1-yl)benzamide; 367 312.1 4-(3-ethyl-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 368 394.2 2-(cyclohexylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 369 410.2 2-[(1-methylpiperidin-4-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 370 353.1 2-(cyclopropylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 371 352.1 2-(cyclopropylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 372 366.2 2-[(cyclopropylmethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 373 448.2 2-[(3,4-dimethoxyphenyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 374 449.2 2-[(3,4-dimethoxyphenyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 375 479.2 2-[(3,4,5-trimethoxyphenyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 376 519.2 2-({3-[3-(dimethylamino)propoxy]-4- methoxyphenyl}amino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 377 411.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 378 409.2 2-[(4-oxocyclohexyl)amino]-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 379 412.1 2-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)phenyl]amino}- 2-oxoethyl acetate; 380 385.2 2-[(3-methoxypropyl)amino]-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 381 421.2 2-{[3-(1H-imidazol-1-yl)propyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 382 467.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}cyclohexyl glycinate; 383 355.2 2-[(2-aminoethyl)amino]-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 384 452.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}cyclohexyl acetate; 385 383.2 4-(3-ethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)-2-[(tetrahydrofuran-2- ylmethyl)amino]benzamide; 386 413.2 2-[(1,4-dioxan-2-ylmethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 387 393.1 2-[(2-furylmethyl)amino]-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 388 392.1 2-[(2-furylmethyl)amino]-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 389 425.2 2-[(2-piperazin-1-ylethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 390 424.2 2-[(2-piperazin-1-ylethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 391 506.2 2-({3-[2-(dimethylamino)ethoxy]-4- methoxyphenyl}amino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 392 352.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide; 393 353.1 2-(allylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 394 468.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexyl glycinate; 395 411.2 2-[(cis-4-hydroxycyclohexyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 396 324 4-[4-oxo-3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 397 398.2 4-(3-ethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)-N′-hydroxy-2-[(tetrahydrofuran-2- ylmethyl)amino]benzenecarboximidamide; 398 424.2 2-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 399 423.2 2-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indol-1-yl)benzamide; 400 384.2 2-{[2-(dimethylamino)ethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 401 495.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}cyclohexyl N,N- dimethylglycinate; 402 332.1 3-chloro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 403 299.1 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzoic acid; 404 390.1 2-(pyridin-3-ylamino)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 405 407.1 2-(pyridin-4-ylthio)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 406 452.2 2-[(1-glycylpiperidin-4-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 407 314.1 N-hydroxy-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 408 356.1 N-(2-methoxyethyl)-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 409 416.2 2-{[(1R)-1-phenylethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 410 423.2 2-[(1-ethylpiperidin-3-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 411 416.2 2-{[(1S)-1-phenylethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 412 417.2 2-{[(1S)-1-phenylethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 413 424.2 2-[(trans-4-methoxycyclohexyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 414 438.2 2-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 415 574.2 2-({3-[3-(dimethylamino)propoxy]-4- methoxyphenyl}amino)-4-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 416 447.1 2-(2,1,3-benzothiadiazol-4-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 417 423.1 2-[(3-chlorophenyl)amino]-4-(3,6,6-trimethyl-4- oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 418 419.2 2-[(3-methoxyphenyl)amino]-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 419 477.2 2-({2-[2-(dimethylamino)ethoxy]pyridin-4- yl}amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 420 465.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans- 4-hydroxycyclohexyl)amino]benzamide; 421 451.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- (tetrahydro-2H-pyran-4-ylamino)benzamide; 422 445.2 2-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 423 445.2 2-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 424 433.1 3-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}benzoic acid; 425 496.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexyl N,N- dimethylglycinate; 426 430.1 2-[(1-oxidotetrahydro-2H-thiopyran-4-yl)oxy]-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 427 446.1 2-[(1,1-dioxidotetrahydro-2H-thiopyran-4- yl)oxy]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 428 382.2 4-(3-methyl-4-oxo-5,6,7,8- tetrahydrocyclohepta[b]pyrrol-1(4H)-yl)-2- (tetrahydro-2H-pyran-4-ylamino)benzamide; 429 387.1 2-{[2-(methylthio)ethyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 430 560.2 2-({3-[2-(dimethylamino)ethoxy]-4- methoxyphenyl}amino)-4-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 431 531.2 2-({2-[2-(dimethylamino)ethoxy]pyridin-4- yl}amino)-4-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 432 511.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexyl(acetyloxy)acetate; 433 413.1 2-(tetrahydro-2H-thiopyran-4-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 434 429.1 2-[(1-oxidotetrahydro-2H-thiopyran-4-yl)amino]- 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 435 445.2 2-[(1,1-dioxidotetrahydro-2H-thiopyran-4- yl)amino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 436 432.2 2-{[3-(aminocarbonyl)phenyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 437 379.2 2-(cyclopent-3-en-1-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 438 395.1 2-[(2,2,2-trifluoroethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 439 413.2 2-{[(3R,4S)-3,4-dihydroxycyclopentyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 440 420.2 2-[(6-methoxypyridin-3-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 441 420.2 2-[(1-methyl-6-oxo-1,6-dihydropyridin-3- yl)amino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 442 483.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexyl methoxyacetate; 443 491.2 2-({1-[3-(dimethylamino)propyl]-6-oxo-1,6- dihydropyridin-3-yl}amino)-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 444 424.2 2-{[2-(2-oxopyrrolidin-1-yl)ethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 445 473.1 2-{[3-(trifluoromethoxy)phenyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 446 433.2 4-[3-(difluoromethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- (tetrahydro-2H-pyran-4-ylamino)benzamide; 447 447.2 4-[3-(difluoromethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans- 4-hydroxycyclohexyl)amino]benzamide; 448 467.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- (tetrahydro-2H-thiopyran-4-ylamino)benzamide; 449 449.1 4-[3-(difluoromethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- (tetrahydro-2H-thiopyran-4-ylamino)benzamide; 450 385.2 2-[(2-methoxy-1-methylethyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 451 460.2 N-(2-aminophenyl)-3-butoxy-4-(2,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 452 410.2 2-{[(3S)-6-oxopiperidin-3-yl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 453 482.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexyl L-alaninate; 454 482.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexyl D-alaninate; 455 481.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}cyclohexyl L-alaninate; 456 481.2 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}cyclohexyl D-alaninate; 457 427.1 1-[4-(aminocarbonyl)-3-(tetrahydro-2H-pyran-4- ylamino)phenyl]-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazole-3-carboxylic acid; 458 475.1 5-bromo-2-[(tetrahydrofuran-2-ylmethyl)amino]- 4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 459 411.2 2-[(3-hydroxycyclohexyl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 460 439.2 4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}cyclohexanecarboxylic acid; 461 522.2 Trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4- oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]phenyl}amino)cyclohexyl glycinate; 462 509.3 Trans-4-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)phenyl]amino}cyclohexyl L-valinate; 463 429.2 2-[(2,6-dihydroxytetrahydro-2H-pyran-4- yl)amino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 464 433.1 2-(cyclopent-3-en-1-ylamino)-4-[6,6-dimethyl-4- oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 465 445.2 4-[3-(difluoromethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(4- oxocyclohexyl)amino]benzamide; 466 463.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(4- oxocyclohexyl)amino]benzamide; 467 483.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(1- oxidotetrahydro-2H-thiopyran-4- yl)amino]benzamide; 468 465.1 4-[3-(difluoromethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(1- oxidotetrahydro-2H-thiopyran-4- yl)amino]benzamide; 469 393.2 2-(cyclohex-3-en-1-ylamino)-4-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)benzamide; 470 427.2 2-{[(3S,4R)-3,4-dihydroxycyclohexyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 471 473.1 2-{[4-(trifluoromethoxy)phenyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 472 504.2 trans-4-({2-(aminocarbonyl)-5-[3- (difluoromethyl)-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1- yl]phenyl}amino)cyclohexyl glycinate; 473 467.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(3- ethynylphenyl)amino]benzamide; 474 383.2 4-(6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)-2-(tetrahydro-2H-pyran-4- ylamino)benzamide; 475 492.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-{[3-(2- oxopyrrolidin-1-yl)propyl]amino}benzamide; 476 365.1 4-(trifluoromethyl)-3-(2,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide; 477 465.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(cis-4- hydroxycyclohexyl)amino]benzamide; 478 435.1 2-{[3-(methylthio)phenyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 479 366.1 4-(trifluoromethyl)-3-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 480 338.1 3-(3-methyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)-4-(trifluoromethyl)benzamide; 481 465.2 2-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-4-[(trans- 4-hydroxycyclohexyl)amino]benzamide; 482 450.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- (piperidin-4-ylamino)benzamide; 483 492.2 2-[(1-acetylpiperidin-4-yl)amino]-4-[6,6- dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 484 540.2 2-[(1-benzylpiperidin-4-yl)amino]-4-[6,6- dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 485 521.2 4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]phenyl}amino)-N,N- dimethylpiperidine-1-carboxamide; 486 445 2-bromo-4-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]-N′-hydroxybenzenecarboximidamide; 487 526.2 2-[(1-benzylpyrrolidin-3-yl)amino]-4-[6,6- dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 488 526.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(1- phenylpiperidin-4-yl)amino]benzamide; 489 524.2 ({[(4E)-1-[4-(aminocarbonyl)-3-(tetrahydro-2H- pyran-4-ylamino)phenyl]-6,6-dimethyl-3- (trifluoromethyl)-1,5,6,7-tetrahydro-4H- indazol-4-ylidene]amino}oxy)acetic acid; 490 471.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-{[2- hydroxy-1,1- bis(hydroxymethyl)ethyl]amino}benzamide; 491 437.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(3R)- tetrahydrofuran-3-ylamino]benzamide; 492 536.2 trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4- oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]phenyl}amino)cyclohexyl L- alaninate; methanesulfonate 493 564.2 trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4- oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]phenyl}amino)cyclohexyl L-valinate methanesulfonate; 494 505.2 2-[allyl(trans-4-hydroxycyclohexyl)amino]-4- [6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide; 495 536.2 2-Amino-propionic acid trans-4-[2-carbamoyl-5- (6,6-dimethyl-4-oxo-3-trifluoromethyl-4,5,6,7- tetrahydro-indazol-1-yl)-phenylamino]- cyclohexyl ester; 496 513.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-(4- pyridin-2-ylpiperazin-1-yl)benzamide; 497 539.2 2-[(2,3-dihydroxypropyl)(trans-4- hydroxycyclohexyl)amino]-4-[6,6-dimethyl-4-oxo- 3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 498 507.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans- 4-hydroxycyclohexyl)(2- oxoethyl)amino]benzamide; 499 441.1 2-[(2,3-dihydroxypropyl)amino]-4-[6,6-dimethyl- 4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro- 1H-indazol-1-yl]benzamide; 500 442.1 2-[(2,3-dihydroxypropyl)amino]-4-[6,6-dimethyl- 4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro- 1H-indazol-1-yl]benzoic acid; 501 597.2 2-(acetoxymethyl)-2-(2-carbamoyl-5-(6,6- dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl)phenylamino)propane- 1,3-diyl diacetate; 502 555.2 2-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]phenyl}amino)-2- (hydroxymethyl)propane-1,3-diyl diacetate; 503 513.1 2-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]phenyl}amino)-3-hydroxy-2- (hydroxymethyl)propyl acetate; 504 509.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans- 4-hydroxycyclohexyl)(2- hydroxyethyl)amino]benzamide; 505 555.1 2-({4-[2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl)ethyl]phenyl}amino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 506 550.3 2-({1-[3-(4-methylpiperazin-1- yl)propanoyl]piperidin-4-yl}amino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 507 501.2 2-[(1-isonicotinoylpiperidin-4-yl)amino]-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 508 501.2 2-{[1-(pyridin-3-ylcarbonyl)piperidin-4- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 509 422.2 2-(1-azabicyclo[2.2.2]oct-3-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 510 460.1 2-{[(3R)-1-(methylsulfonyl)pyrrolidin-3- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 511 467.2 2-[(1-beta-alanylpiperidin-4-yl)amino]-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 512 493.2 2-[(1-prolylpiperidin-4-yl)amino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 513 424.2 2-{[(3R)-1-acetylpyrrolidin-3-yl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 514 453.2 (3R)-3-{[2-(aminocarbonyl)-5-(3,6,6-trimethyl- 4-oxo-4,5,6,7-tetrahydro-1H-indazol-1- yl)phenyl]amino}-N,N-dimethylpyrrolidine-1- carboxamide; 515 523.2 [[2-Carbamoyl-5-(6,6-dimethyl-4-oxo-3- trifluoromethyl-4,5,6,7-tetrahydro-indazol-1- yl)-phenyl]-(trans-4-hydroxy-cyclohexyl)- amino]-acetic acid; 516 419.2 2-{[4-(hydroxymethyl)phenyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 517 451.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- {[(1R,3S)-3-hydroxycyclopentyl]amino}benzamide; 518 451.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2- {[(1R,3R)-3-hydroxycyclopentyl]amino}benzamide; 519 397.2 2-{[(2R)-tetrahydrofuran-2-ylmethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 520 505.2 2-{[trans-4-(allyloxy)cyclohexyl]amino}-4-[6,6- dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 521 397.2 2-{[(2S)-tetrahydrofuran-2-ylmethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 522 473.2 2-[(1-isonicotinoylazetidin-3-yl)amino]-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 523 473.2 2-{[1-(pyridin-3-ylcarbonyl)azetidin-3- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 524 509.2 2-{[1-(3-morpholin-4-ylpropanoyl)azetidin-3- yl]amino}-4-(3,6,6-trimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 525 522.3 2-({1-[3-(4-methylpiperazin-1- yl)propanoyl]azetidin-3-yl}amino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 526 401.1 2-{[3-(methylthio)propyl]amino}-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide; 527 437.1 2-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-4-[(3R)- tetrahydrofuran-3-ylamino]benzamide; 528 385.2 2-{[(1S)-2-methoxy-1-methylethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 529 396.2 2-(tetrahydro-2H-pyran-2-ylamino)-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1- yl)benzamide; 530 655.3 2-[[trans-4-(allyloxy)cyclohexyl](3,5- dimethoxybenzyl)amino]-4-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 531 689.3 2-[[trans-4-(2,3- dihydroxypropoxy)cyclohexyl](3,5- dimethoxybenzyl)amino]-4-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 532 404.1 4-{3-[(benzyloxy)methyl]-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl}benzamide; 533 448.2 2-({2-[(dimethylamino)sulfonyl]ethyl}amino)-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 534 382.2 2-[(3S)-pyrrolidin-3-ylamino]-4-(3,6,6- trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol- 1-yl)benzamide hydrochloride; 535 424.2 2-{[(3S)-1-acetylpyrrolidin-3-yl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 536 507.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-{[trans- 4-(2-oxoethoxy)cyclohexyl]amino}benzamide; 537 539.2 2-{[4-(2,3-dihydroxypropoxy)cyclohexyl]amino}- 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide; 538 516.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-({2- [(isopropylsulfonyl)amino]ethyl}amino)benzamide; 539 509.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-{[trans- 4-(2-hydroxyethoxy)cyclohexyl]amino}benzamide; 540 523.2 {[trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl- 4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro- 1H-indazol-1- yl]phenyl}amino)cyclohexyl]oxy}acetic acid; 541 550.1 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-({2- [(phenylsulfonyl)amino]ethyl}amino)benzamide; 542 490.2 2-{[2-(morpholin-4-ylsulfonyl)ethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide; 543 327.1 4-[3-(2-aminoethyl)-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl]benzamide; 544 451.1 2-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-4- {methyl[(3R)-tetrahydrofuran-3- yl]amino}benzamide; 545 439.1 2-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-4-[(2- methoxy-1-methylethyl)amino]benzamide; 546 430 4-bromo-2-[6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydro-1H- indazol-1-yl]benzamide; 547 425.2 4-(3-ethyl-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)-2-[(trans-4- hydroxycyclohexyl)amino]benzamide; 548 522.2 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans- 4-{[(2E)-2- (hydroxyimino)ethyl]oxy}cyclohexyl)amino]benzamide; 549 453.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(3- isobutyl-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro- 1H-indazol-1-yl)benzamide; 550 437.2 4-(3-cyclopropyl-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)-2-[(trans-4- hydroxycyclohexyl)amino]benzamide; 551 426.2 4-[3-(aminomethyl)-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl]-2-[(trans-4- hydroxycyclohexyl)amino]benzamide methanesulfonate (salt); 552 452.2 2-[(1-methyl-2-oxo-2-piperidin-1- ylethyl)amino]-4-(3,6,6-trimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide; 553 440.2 4-[3-(2-aminoethyl)-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl]-2-[(trans-4- hydroxycyclohexyl)amino]benzamide; 554 439.2 2-[(trans-4-hydroxycyclohexyl)amino]-4-(3- isopropyl-6,6-dimethyl-4-oxo-4,5,6,7- tetrahydro-1H-indazol-1-yl)benzamide; 555 437.1 2-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-4- (tetrahydrofuran-3-ylamino)benzamide; 556 451.2 4-[3-(cyclopropylmethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans- 4-hydroxycyclohexyl)amino]benzamide; 557 424.2 2-[(trans-4-hydroxycyclohexyl)amino]-4- (2,3,6,6-tetramethyl-4-oxo-4,5,6,7-tetrahydro- 1H-indol-1-yl)benzamide; 558 338.1 4-[3-(cyclopropylmethyl)-6,6-dimethyl-4-oxo- 4,5,6,7-tetrahydro-1H-indazol-1-yl]benzamide; 559 398.2 2-{[2-(dimethylamino)-2-oxoethyl]amino}-4- (3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H- indazol-1-yl)benzamide;

Example 47

Additional compounds of the invention are represented by Formula XXIII and have substituents R₃, R₄, R₅, R₆, R₇, Q₁, Q₂, Q₃, Y, X₁, and X₂ as listed in the tables below. These compounds are prepared essentially according to the procedures set forth in Schemes 1-9 above and described in the above examples.

TABLE A1 Substructures and codes for R₃, R₄

001

002

003

004

005

006

007

010

011

012

013

014

015

016

017

018

019

020

021

022

023

024

030

031

032

033

034

035

036

040

041

042

043

044

045

046

050

051

052

053

054

055

060

061

062

063

064

065

070

071

072

073

074

075

076

080

081

082

083

084

085

TABLE A2 Substructures and codes for R₃, R₄

110

111

112

113

114

120

121

122

123

TABLE A3 Substructures and codes for R₃, R₄

140

141

142

142

144

150

151

152

153

154

155

160

161

162

163

164

170

172

173

174

175

176

180

181

182

183

184

185

190

191

TABLE A4 Substructures and codes for R₃, R₄

210

211

212

213

214

220

221

222

223

224

TABLE A5 Substructures and codes for R₃, R₄

240

241

242

243

244

250

251

252

253

254

255

256

260

261

262

263

264

270

271

272

273

274

275

280

281

282

283

284

285

TABLE A6 Substructures and codes for R₃, R₄

300

301

302

303

310

311

312

313

320

321

322

323

324

330

331

332

333

340

341

342

343

344

350

351

352

353

354

355

360

361

362

363

364

370

371

372

373

374

375

380

381

382

383

384

390

391

392

393

394

395

TABLE A7 Substructures and codes for R₃, R₄

410

411

412

413

420

421

422

423

424

425

430

431

432

433

434

TABLE A8 Substructures and codes for R₃, R₄

450

451

452

453

454

455

456

460

461

462

463

464

465

470

471

472

473

474

475

480

481

482

483

484

485

486

490

491

492

493

494

500

501

502

503

504

505

TABLE A9 Substructures and codes for R₃, R₄

520

521

522

523

524

525

530

531

532

533

534

540

541

542

543

544

550

551

552

553

554

555

560

561

562

563

564

565

570

571

572

573

574

580

581

582

583

584

585

586

587

TABLE B Substructures and codes for Q₂, Q₁, Q₃ N B00 C—H B01 C—C≡N B02 C—CH₃ B03 C—NH₂ B04 C—CH₂CH₃ B05 C—CF₃ B06 C—Br B07 C—Cl B08 C—F B09

B10

B11

B12

B13

B14

B15

B16

B17

B20

B21

B22

B23

B24

B25

B30

B31

B32

B33

B34

B35

B40

B41

B42

B43

B44

B45

TABLE C Substructures and codes for X₁, Y N C00 C—H C01 C—CF₃ C02 C—CHF₂ C03 C—CH₂F C04 C—C≡N C05 C—NO₂ C06 C—Cl C07 C—Br C08

C09 C—C≡CH C10

C20

C21

C22

C23

C24

C25

C26

C27

C28

C29

C30

C31

C32

C33

C34

C35

C36

C37

TABLE D Substructures and codes for R₇

D00

D01

D02

D03

D04

D05

D06 O D07 S D08

D10

D11

D12

TABLE E Substructures and codes for X₂ (R₅, R₆)

E00

E01

E02

E03

E04

E05

E10

E11

E12

E13

E14

E15

Biological Evaluation Example 48 Cell Proliferation Assays

A panel of cancer cell lines was obtained from the DCTP Tumor Repository, National Cancer Institute (Frederick, Md.) or ATCC (Rockville, Md.). Cell cultures were maintained in Hyclone RPMI 1640 medium (Logan, Utah) supplemented with 10% fetal bovine serum and 20 mM HEPES buffer, final pH 7.2, at 37° C. with a 5% CO₂ atmosphere. Cultures were maintained at sub-confluent densities. Human umbilical vein endothelial cells (HUVEC) were purchased from Clonetics, a division of Cambrex (Walkersville, Md.). Cultures were established from cryopreserved stocks using Clonetics EGM-2 medium supplemented with 20 mM HEPES, final pH 7.2, at 37° C. with a 5% CO₂ atmosphere.

For proliferation assays, cells were seeded with the appropriate medium into 96 well plates at 1,000-2,500 cells per well, depending on the cell line, and were incubated overnight. The following day, test compound, DMSO solution (negative control), or Actinomycin D (positive control) was added to the appropriate wells as 10× concentrated stocks prepared in phosphate buffered saline. The cell plates were then incubated for an additional 2-5 days, depending on the cell line, to allow proliferation to occur. To measure cell density, 50 μL of WST-1 solution (Roche Applied Science, IN) diluted 1:5 in phosphate buffered saline was added to each well, and the cells incubated for an additional 1-5 hrs., again depending on the cell line. Optical density was determined for each well at 450 nM using a Tecan GeniosPro plate reader (RTP, NC). The percentage of cell growth was determined by comparing the cell growth in the presence of test compounds to the cells treated with DMSO vehicle (control, 100% growth) and cells treated with Actinomycin D (10 μM, 0% growth).

Immediately after the WST-1 determination, the medium was removed from the PC-3, NCI-H460 and HUVEC cell lines, and the plates stored at −80° C. Using these assay plates, relative amounts of DNA in each well were determined using the Cyquant DNA assay kit from R&D Systems (Eugene, Oreg.) following the manufacturer's directions. Results for each compound treatment were compared to DMSO vehicle control (100%) and 10 μM Actinomycin D treated cells (0%).

Several exemplary compounds useful in the methods of the invention are listed below. The range of their inhibitory activity against PC-3 cell proliferation is demonstrated, where +++ stands for an IC₅₀ value that is less than 0.5 M, ++ between 0.5 and 5 μM, + between 5 and 50 μM.

Compound 70 + Compound 72 ++ Compound 74 + Compound 76 ++ Compound 77 + Compound 81 +++ Compound 82 ++ Compound 84 ++ Compound 93 ++ Compound 94 + Compound 5 ++ Compound 53 + Compound 55 ++ Compound 97 +++ Compound 98 +++ Compound 99 + Compound 100 +++ Compound 19 +++ Compound 101 ++ Compound 102 + Compound 103 ++ Compound 27 +++ Compound 104 +++ Compound 105 + Compound 106 ++ Compound 108 +++ Compound 110 + Compound 112 + Compound 113 +++ Compound 114 +++ Compound 31 +++ Compound 116 +++ Compound 117 +++ Compound 121 ++ Compound 123 ++ Compound 124 +++ Compound 127 +++ Compound 129 ++ Compound 133 + Compound 136 ++

Example 49 Determination of Affinity for HSP-90

(Heat Shock Protein 90)

Affinity of test compounds for HSP-90 was determined as follows: Protein mixtures obtained from a variety of organ tissues (for example: spleen, liver and lung) were reversibly bound to a purine affinity column to capture purine-binding proteins, especially HSP-90. The purine affinity column was washed several times, and then eluted with 20 μM, 100 μM, and 500 μM of test compound. Compounds of Formula I elute HP-90 in a dose-dependent manner vs. a control elution using dimethylsulfoxide. The elution profile of Formula I compounds was determined by 1-dimensional SDS polyacrylamide gel electrophoresis. Gels were stained with a fluorescent stain such as sypro ruby (a highly sensitive fluorescent protein stain that can readily detect less than 1 fmol of total protein, i.e., less than 0.04 ng for a 40 kDa protein) or silver nitrate. The gels were imaged using a standard flat bed gel imager and the amount of protein estimated by densitometry. The percent of HSP-90 protein eluted from the column at each concentration was determined and IC₅₀ values were calculated from these estimates. The identity of a band containing HSP-90 was determined by protein sequencing using mass spectroscopy.

Compounds of the invention are inhibitors of HSP-90 (heat shock protein 90). Several exemplary compounds useful in the methods of the invention are listed below. The range of their relative binding affinity to HSP-90 is demonstrated, where +++ stands for very high, ++ for high and + for moderate.

Compound 30 ++ Compound 70 + Compound 73 + Compound 75 +++ Compound 76 +++ Compound 77 ++ Compound 78 + Compound 79 + Compound 80 + Compound 83 +++ Compound 86 ++ Compound 87 ++ Compound 88 ++ Compound 91 ++ Compound 92 ++ Compound 94 ++ Compound 50 +++ Compound 53 ++ Compound 95 +++ Compound 54 + Compound 55 ++ Compound 96 +++ Compound 98 +++ Compound 99 ++ Compound 102 ++ Compound 103 ++ Compound 105 ++ Compound 34 ++ Compound 107 ++ Compound 109 ++ Compound 111 +++ Compound 115 +++ Compound 32 +++ Compound 117 +++ Compound 121 +++ Compound 131 ++ Compound 132 +++ Compound 133 ++ Compound 134 ++ Compound 135 +++

The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the invention and that modifications may be made therein without departing from the spirit or scope of the invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification. 

What is claimed is:
 1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein R₁ and R₂ are independently H or C₁-C₆ alkyl; R₄ is hydrogen; R₃ is (a) halo, or (b) a C₁-C₁₅ alkyl group where up to six of the carbon atoms in said alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other, wherein R₂₂ is (i) heteroaryl, (ii) aryl, (iii) saturated or unsaturated C₃-C₁₀ cycloalkyl, or (iv) saturated or unsaturated C₂-C₁₀ heterocycloalkyl, wherein each aryl, heteroaryl, saturated or unsaturated cycloalkyl, or saturated or unsaturated heterocycloalkyl, independently, is optionally substituted with at least one group, which independently is hydroxy, halo, amino, cyano, carboxy, carboxamido, nitro, oxo, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, —SO-aryl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, (C₁-C₆)alkoxy, or mono- or di-(C₁-C₁₀)alkylamino; and each R₂₂ is optionally fused to a C₆-C₁₀ aryl group, C₅-C₈ saturated cyclic group, or a C₅-C₁₀ heterocycloalkyl group; wherein each (b) is optionally substituted at any available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃, wherein Z is OR₀ or —N(R₃₀)₂, wherein each R₃₀ is independently H or C₁-C₆ alkyl, or N(R₃₀)₂ represents pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,3- or 1,4-diazepanyl, or morpholinyl, each of which is optionally substituted with hydroxy, amino, aminoalkyl, C₁-C₆ alkyl, mono- or di(C₁-C₆)alkylamino, C₁-C₆ alkoxy, or halogen; R_(O) is H, —C₁-C₁₀ alkyl, —C₂-C₁₀ alkenyl, —C₂-C₁₀ alkynyl, aryl, heteroaryl, or —C₁-C₆ acyl; R₂₃ is (1) heteroaryl, (2) aryl, (3) saturated or unsaturated C₅-C₁₀ cycloalkyl, or (4) saturated or unsaturated C₅-C₁₀ heterocycloalkyl, and the R₂₃ groups are optionally substituted with at least one group which independently is hydroxy, oxo, halo, amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, —SO-aryl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, (C₁-C₆)alkoxy, or mono- or di-(C₁-C₁₀)alkylamino; R_(C) is hydrogen, halogen, cyano, nitro, —C(O)R_(C′), C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇ cycloalkyl(C₁-C₁₀)alkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each alkyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl group is optionally substituted with from 1-4 groups that are independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, amino, mono- or di-(C₁-C₆) alkylamino, cyano, nitro, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, carboxamide, heterocycloalkyl, aryl, or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted with from 1-4 groups that are independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, amino, mono- or di-(C₁-C₆) alkylamino, halo(C₁-C₆)alkyl, or carboxamide; R_(C′) is —C₁-C₆ alkyl, —OR_(C″), or —N(R_(CN))₂, wherein R_(C″) is —H, C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₃-C₇ cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R_(CN) is independently —H, —C₁-C₁₀ alkyl, —C₁-C₁₀-haloalkyl, —C₃-C₇ cycloalkyl, -heterocycloalkyl, —C₁-C₆ acyl, -aryl, or -heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is optionally substituted with from 1-4 groups that are independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, amino, mono- or di-(C₁-C₆) alkylamino, nitro, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, or carboxamide; R₅ and R₆ are independently H, C₁-C₆ alkyl, or aryl, wherein the aryl is optionally substituted with from 1-4 groups that are independently C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, amino, mono- or di-(C₁-C₆) alkylamino, nitro, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, or carboxamide, wherein any two adjacent substituted aryl positions, together with the carbon atoms to which they are attached, form an unsaturated cycloalkyl or heterocycloalkyl; or R₅ and R₆ together with the carbon to which they are attached form a 3-8 membered ring.
 2. A compound according to claim 1, wherein R₃ is halo, or —Z₁R_(Z1), wherein Z₁ is —O— or —NH—; R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other, wherein R_(Z1) is optionally substituted at any available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.
 3. A compound according to claim 1, wherein R₄ is H; and R₃ is —N(H)R_(Z1), wherein R_(Z1) is a C₁-C₁₄ alkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R₂₂, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO₂, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other, wherein R_(Z1) is optionally substituted at any available position with C₁-C₁₀ alkyl, C₁-C₁₀ haloalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH, —S—(C₁-C₆)alkyl, —SO₂—(C₁-C₆)alkyl, —SO₂NH₂, —SO₂NH—(C₁-C₆)alkyl, —SO₂NH-aryl, —SO₂-aryl, —SO—(C₁-C₆)alkyl, C₁-C₆ alkoxy, C₂-C₁₀ alkenyloxy, C₂-C₁₀ alkynyloxy, mono- or di-(C₁-C₁₀)alkylamino, —OC₁-C₁₀ alkyl-Z, or R₂₃.
 4. A compound according to claim 3, wherein R_(C) is methyl, ethyl, cyclopropyl, cyclopropylmethyl, fluoromethyl, difluoromethyl, or trifluoromethyl.
 5. A compound according to claim 1 which is 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide; 4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate; or a pharmaceutically acceptable salt thereof.
 6. A pharmaceutical composition comprising at least one compound or salt according to claim 1 and a pharmaceutically acceptable solvent, carrier, excipient, adjuvant or a combination thereof.
 7. A pharmaceutical composition comprising at least one compound or salt according to claim 5 and a pharmaceutically acceptable solvent, carrier, excipient, adjuvant or a combination thereof.
 8. A compound according to claim 1 which is 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]benzamide; Trans-4-({2-(am inocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate; or a pharmaceutically acceptable salt thereof.
 9. A pharmaceutical composition comprising at least one compound or salt according to claim 8 and a pharmaceutically acceptable solvent, carrier, excipient, adjuvant or a combination thereof. 